Citation for final published version:

Vandervore, Laura V., Schot, Rachel, Milanese, Chiara, Smits, Daphne J., Kasteleijn, Esmee, Fry, Andrew E. , Pilz, Daniela T., Brock, Stefanie, Börklü-Yücel, Esra, Post, Marco, Bahi-Buisson, Nadia, Sánchez-Soler, María José, van Slegtenhorst, Marjon, Keren, Boris, Afenjar, Alexandra, Coury, Stephanie A., Tan, Wen-Hann, Oegema, Renske, de Vries, Linda S., Fawcett, Katherine A., Nikkels, Peter G.J., Bertoli-Avella, Aida, Al Hashem, Amal, Alwabel, Abdulmalik A., Tlili-Graiess, Kalthoum, Efthymiou, Stephanie, Zafar, Faisal, Rana, Nuzhat, Bibi, Farah, Houlden, Henry, Maroofian, Reza, Person, Richard E., Crunk, Amy, Savatt, Juliann M., Turner, Lisbeth, Doosti, Mohammad, Karimiani, Ehsan Ghayoor, Saadi, Nebal Waill, Akhondian, Javad, Lequin, Maarten H., Kayserili, Hülya, van der Spek, Peter J., Jansen, Anna C., Kros, Johan M., Verdijk, Robert M., Milosevic, Natasa Jovanov, Fornerod, Maarten, Mastroberardino, Pier Giorgio and Mancini, Grazia M.S. 2019. TMX2 Is a crucial regulator of cellular redox state, and Its dysfunction causes severe brain developmental abnormalities. American Journal of Human Genetics 105 (6) , pp. 1126-1147. 10.1016/j.ajhg.2019.10.009

Publishers page: http://dx.doi.org/10.1016/j.ajhg.2019.10.009

1 **TMX2 is a crucial regulator of cellular redox state and its dysfunction causes severe brain**
2 **developmental abnormalities.**

3 Laura V.Vandervore[1,2,3]*, Rachel Schot[1]*, Chiara Milanese[4], Daphne J. Smits[1], Esmee Kasteleijn[1],
4 Andrew E. Fry[5.6], Daniela T. Pilz[7], Stefanie Brock[2,8], Esra Börklü-Yücel[1,9,10], Marco Post [9] , Nadia Bahi-
5 Buisson[11], María José Sánchez-Soler [12], Marjon van Slegtenhorst[1], Boris Keren[13], Alexandra Afenjar[14],
6 Stephanie Coury[15], Wen-Hann Tan[15,16], Renske Oegema[17], Linda S. de Vries[18], Katherine A.
7 Fawcett[19,20], Peter G.J. Nikkels[21], Aida Bertoli-Avella[22], Amal Al Hashem[23], Abdulmalik A. Alwabel[24],
8 Kalthoum Tlili-Graiess[25], Stephanie Efthymiou[26], Faisal Zafar[27], Nuzhat Rana[27], Farah Bibi[28], Henry
9 Houlden[29], Reza Maroofian[29], Richard E. Person[30], Amy Crunk[30], Juliann M. Savatt[31], Lisbeth Turner[31]
10 , Mohammad Doosti[32] , Ehsan Ghayoor Karimiani[33, 34] , Nebal Waill Saadi[35] , Javad Akhondian[36] ,
11 Maarten H. Lequin[37], Hülya Kayserili[10], Peter J. van der Spek[38], Anna C. Jansen[2,39], Johan M. Kros[40],
12 Robert M. Verdijk[40], Nataša Jovanov Milošević[41], Maarten Fornerod[9], Pier Giorgio
13 Mastroberardino[4,42], Grazia M. S. Mancini[1]**

14 *authors contributed equally

15 ** corresponding author: Grazia M.S. Mancini, Department of Clinical Genetics, Erasmus University
16 Medical Center, 3000 CA Rotterdam, The Netherlands.
17 Email: g.mancini@erasmusmc.nl
18

19 **Author affiliations:**

20 [1]Department of Clinical Genetics, Erasmus University Medical Center (Erasmus MC), P.O. Box 2040,
21 3000 CA Rotterdam, The Netherlands

22 [2]Neurogenetics Research Group, Research Cluster Reproduction, Genetics and Regenerative
23 Medicine, Vrije Universiteit Brussel, Brussels, 1090, Belgium

24 [3]Center for Medical Genetics, UZ Brussel, Brussels, 1090, Belgium

25 [4]Department of Molecular Genetics, Erasmus University Medical Center (Erasmus MC), P.O. Box
26 2040, 3000 CA Rotterdam, The Netherlands

27 [5] Institute of Medical Genetics, University Hospital of Wales, Cardiff CF14 4XW, UK

28 [6]Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK

29 [7]West of Scotland Clinical Genetics Service, Queen Elizabeth University Hospital, Glasgow G51 4TF,
30 UK

31 [8]Department of Pathology, UZ Brussels, Brussels, 1090, Belgium

32 [9]Department of Cell Biology, Erasmus University Medical Center (Erasmus MC), P.O. Box 2040, 3000
33 CA Rotterdam, The Netherlands

34 [10]Medical Genetics Department, Koç University School of Medicine (KUSoM), Istanbul, 34010, Turkey

[11]Imagine Institute, INSERM UMR-1163, Laboratory Genetics and Embryology of Congenital Malformations, Paris Descartes University, Institut des Maladies Génétiques 24, Boulevard de Montparnasse, Paris, 75015, France.

[12]Sección Genética Médica, Servicio de Pediatría, Hospital Clínico Universitario Virgen de la Arrixaca. IMIB-Arrixaca, Murcia, 30120, España.

[13]Département de génétique, Hôpital Pitié-Salpêtrière, Assistance Publique – Hôpitaux de Paris, Paris, 75013, France

[14]Département de génétique et embryologie médicale, CRMR des malformations et maladies congénitales du cervelet et des déficits intellectuels de causes rares, GRC ConCer-LD, Sorbonne Universités, Hôpital Trousseau, Paris, 75012, France.

[15]Division of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts, 02115, USA

[16]Harvard Medical School, Boston, Massachusetts, 02115, USA

[17]Department of Genetics, University Medical Center Utrecht (UMCU), Utrecht University, 3584 CX, the Netherlands

[18]Department of Neonatology, University Medical Center Utrecht (UMCU), Utrecht University, 3584 CX, the Netherlands

[19]MRC Computational Genomics Analysis and Training Programme (CGAT), MRC Centre for Computational, Biology, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK

[20]Present address: Department of Health Sciences, University of Leicester, George Davies Centre, University Road, Leicester LE1 7RH, UK

[21]Department of Pathology, University Medical Center Utrecht (UMCU), Utrecht University, 3584 CX, the Netherlands

[22]Centogene AG, Rostock, 18055, Germany

[23]Division of Medical Genetic, Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, 12233, Saudi Arabia

[24]Division of General Pediatrics, Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, 12233, Saudi Arabia

[25]Division of Neuroradiology, Department of Radiology, Prince Sultan Military Medical City, Riyadh, 12233, Saudi Arabia.

[26] Department of Neuromuscular Disorders, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK

[27]Department of Pediatric Neurology, Children's hospital and institute of Child health, Multan 60000, Pakistan

69 [28]University Institute of Biochemistry & Biotechnology, PMAS – Arid Agriculture University, Rawalpindi, 43600, Pakistan
70

71 [29]Department of Neuromuscular Disorders, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK
72

73 [30]GeneDx, 207 Perry Parkway, Gaithersburg, MD, 20877, USA

74 [31]The Autism & Developmental Medicine Institute at Geisinger in Danville, PA 17822. USA

75 [32]Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 8415683111, Iran
76

77 [33]Molecular and Clinical Sciences Institute, St. George's, University of London, Cranmer TerraceLondon, SW17 ORE, UK
78

79 [34]Innovative medical research center, Mashhad branch, Islamic Azdad University, Mashhad 9133736351, Iran
80

81 [35]College of Medicine / Baghdad University, Children Welfare Teaching Hospital - Medical City Complex – Baghdad 10001, Iraq
82

83 [36]Department of Pediatric Neurology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad 8415683111, Iran
84

85 [37]Department of Radiology, University Medical Center Utrecht (UMCU), Utrecht University, 3584 CX, the Netherlands
86

87 [38]Department of Pathology, Clinical Bio-informatics, Erasmus University Medical Center (Erasmus MC), P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
88

89 [39]Pediatric Neurology Unit, Department of Pediatrics, UZ Brussel, Brussels, 1090, Belgium

90 [40] Department of Pathology, Erasmus University Medical Center (Erasmus MC), P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
91

92 [41]Croatian Institute of Brain Research, School of Medicine, University of Zagreb, 10000, Croatia.

93 [42]Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, 67100, Italy
94

95 Respective e-mail addresses: Laura.Vandervore@vub.be; r.schot@erasmusmc.nl
96 c.milanese@erasmusmc.nl; d.smits@erasmusmc.nl; e.kasteleijn@erasmusmc.nl;
97 FryAE@cardiff.ac.uk; PilzDT@cardiff.ac.uk; Stefanie.Brock@vub.be; eyucel@kuh.ku.edu.tr;
98 425194mp@student.eur.nl; nadia.bahi-buisson@nck.aphp.fr; mj.sanchezsoler@gmail.com;
99 m.vanslegtenhorst@erasmusmc.nl; boris.keren@psl.aphp.fr; alexandra.afenjar@aphp.fr;
100 Stephanie.Coury@childrens.harvard.edu; Wen-Hann.Tan@childrens.harvard.edu;
101 R.Oegema@umcutrecht.nl; L.s.devries@umcutrecht.nl; kath.a.fawcett@googlemail.com;
102 P.G.J.Nikkels@umcutrecht.nl; Aida.Bertoli-Avella@centogene.com; amal.alhashem@gmail.com;
103 jrdr.alwabel@gmail.com; Kalthoum.Tlili@rns.tn; s.efthymiou@ucl.ac.uk ; drfaisal867@yahoo.com;

104   drnuzhatrana@gmail.com; h.houlden@ucl.ac.uk; r.maroofian@ucl.ac.uk ; rperson@genedx.com;

105   acrunk@genedx.com; jmsavatt@geisinger.edu; lturner3@geisinger.edu ; doosti.m@gmail.com ;

106   eghayoor@gmail.com   ;   nebalpedneu2013@gmail.com   ;   akhondianj@mums.ac.ir   ;

107   M.h.lequin@umcutrecht.nl;   hkayserili@kuh.ku.edu.tr;   p.vanderspek@erasmusmc.nl;

108   Anna.Jansen@uzbrussel.be;   j.m.kros@erasmusmc.nl;   r.verdijk@erasmusmc.nl;

109   njovanov@gmail.com;   m.fornerod@erasmusmc.nl;   p.g.mastroberardino@erasmusmc.nl;

110   g.mancini@erasmusmc.nl

ABSTRACT

The redox state of the neural progenitors regulates physiological processes such as neuronal differentiation, dendritic and axonal growth. The relevance of ER-associated oxidoreductases in these processes is largely unexplored. We describe a severe neurological disorder caused by biallelic loss of function variants in Thioredoxin (TRX)-Related Transmembrane-2 (*TMX2*), detected by exome sequencing in fourteen affected individuals from ten unrelated families presenting with congenital microcephaly, cortical polymicrogyria and other migration disorders. *TMX2* encodes one of the five TMX proteins of the Protein Disulfide Isomerase family, hitherto not linked to human developmental brain disease. Our mechanistic studies on protein function show that TMX2 localizes to the ER Mitochondria-Associated-Membranes (MAMs), is involved in posttranslational modification and protein folding, and undergoes physical interaction with the MAM associated and ER folding chaperone calnexin and ER calcium pump SERCA2. These interactions are functionally relevant because *TMX2*-deficient fibroblasts show decreased mitochondrial respiratory reserve capacity and compensatory increased glycolytic activity. Intriguingly, under basal conditions TMX2 occurs in both reduced and oxidized monomeric form, while it forms a stable dimer under treatment with hydrogen peroxide, recently recognized as signaling molecule in neural morphogenesis and axonal pathfinding. Exogenous expression of the pathogenic *TMX2* variants or of variants with *in vitro* mutagenized TRX domain induces a constitutive TMX2 polymerization, mimicking increased oxidative state. Altogether these data uncover TMX2 as a sensor in the MAM-regulated redox signaling pathway and identify it as a key adaptive regulator of neuronal proliferation, migration and organization in the developing brain.

5

INTRODUCTION

The endoplasmic reticulum (ER) is responsible for the folding of one third of the human proteome. Protein folding is coordinated by ER chaperones, together with ER oxidoreductases of the Protein Disulfide Isomerase (PDI) family[1]. This family consists of 23 oxidoreductase proteins[2] and is part of the thioredoxin (TRX) superfamily[3]. PDIs are characterized by the presence of at least one TRX-like domain (potentially catalytically active with sequence including two cysteines, C-X-X-C) and an ER retention domain (typically Lys-Asp-Glu-Leu/ KDEL)[3; 4]. In the oxidizing environment of the ER, PDIs with active site cysteines can oxidize thiol groups of newly synthesized polypeptides mediating protein folding[2; 5], but can also catalyze reduction and isomerization of disulfides in misfolded proteins, facilitating ER-associated degradation (ERAD) during the unfolded protein response (UPR)[6].

PDI mediated protein folding is ATP dependent and relies on precise regulation of calcium influx to the mitochondria, necessary for mitochondrial oxidative phosphorylation[1] [7]. Since the ER is the major storage site for calcium, specialized ion channels are located at the mitochondria-associated membranes (MAMs) of the ER to assure proper calcium transport to and from the ER, e.g. sarcoplasmic-endoplasmic reticulum Ca^{2+}-ATPase ATP2A2/SERCA2, inositol 1,4,5 trisphosphate receptor type 1 (IP3R1) and voltage-dependent anion-selective channel 1 (VDAC1)[1]. Besides regulating protein folding, some PDI oxidoreductases additionally function in calcium trafficking through interaction with these ER calcium channels[1; 8; 9]. Accordingly, some PDIs show enriched ER localization at the MAM[10]. Through upregulation of calcium transport into the mitochondria, PDIs are also able to regulate ATP production, necessary to increase folding mechanisms when misfolded proteins aggregate (ER-stress)[1; 7; 11]. Hence, PDIs and protein folding are important determinants for normal mitochondrial bioenergetics and cell survival.

In humans, altered expression of PDIs has been correlated with neurodegenerative disorders like Alzheimer, Parkinson disease and amyotrophic lateral sclerosis[12]. However, notwithstanding their proven biological relevance, little is known about the consequence of inherited pathogenic variants in PDIs. At the moment of writing, only one heterozygous recurrent variant in *P4HB* (OMIM 176790) (Prolyl 4-hydroxylase, β-subunit) encoding PDIA1has been associated with Cole-Carpenter syndrome 1 (OMIM 112240), characterized by skeletal malformations (OMIM 176790)[12-15]. Pathogenic variants in non-PDI oxidoreductases from other protein families, e.g. *WWOX* (OMIM 605131)[16], *DHCR24* (OMIM 606418) [17], *NDUFS1* (OMIM 157655) [18] , and variants in MAM-associated genes, e.g. *SERAC1* (OMIM 614725) [19], *MFN2* (OMIM 608507) [20], have been linked to neurodevelopmental and mitochondrial disorders.

Thioredoxin (TRX)-Related Transmembrane proteins (TMX) are five type 1 transmembrane proteins belonging to the PDI family[2; 3; 21]. The best studied of the group, TMX1 (PDIA11) is localized at the MAM and regulates calcium trafficking through interaction with the ER calcium pump SERCA2[1] [7]. No pathogenic variants have been reported in TMX members in relation to human disease until now, although two missense variants of unknown significance in *TMX3* were proposed to lead to microphthalmia[22]. TMX2 (PDIA12), one of the least studied of the group, is encoded by *TMX2* on chromosome 11q12.1 (OMIM 616715), is ubiquitously expressed and presents in two isoforms, the longest with 296 amino acids being the most biologically relevant as ER resident protein[21]. The N-terminal signal sequence (amino acid1-48) is followed by the cytosolic domain (amino acid49-102), the single transmembrane domain (amino acid 103-125), the atypical TRX domain (amino acid 167-170, Ser-Asn-Asp-Cys, SNDC), the ER intraluminal C-terminal domain (amino acid 126-296) and a Di-

178   lysine ER retention motif (amino acid 293-296, Lys-Lys-Asp-Lys, KKDK)[3; 4]. It has been suggested that
179   TMX2 is enriched at the MAM location[10]. Because TMX2 does not contain a typical thioredoxin-like
180   active domain (SNDC instead of CXXC), its oxidoreductase activity and role in protein folding have
181   been questioned. However, the importance of *TMX2* is underlined by the non-viability of
182   homozygous *Tmx2*-/- knockout mice (C57BL/6NJ strain, Mouse Genome Informatics MGI:1914208).
183   Here we report microcephaly, polymicrogyria (PMG), complex migration disorders and epilepsy in
184   individuals bearing bi-allelic autosomal recessive variants in *TMX2*. We study the function of normal
185   TMX2 and the effect of the variants in human cells providing a mechanistic understanding of TMX2
186   function in health and disease, linking PDIs to neurodevelopment.

187   **MATERIAL AND METHODS**
188   *Ethics statement and biopsy*
189   The cohort of *TMX2* affected individuals (here coded as P1 to P14) includes 10 families of which four
190   were gathered through the European Network on Brain Malformations, Neuro-MIG (COST Action
191   CA16118), five families through GeneMatcher[23] and one family was earlier described in
192   supplemental data from a cohort of undiagnosed individuals with malformations of cortical
193   development[24]. All study participants or their legal caretakers gave written informed consent to
194   participate in this study and for publication of images, according to Erasmus MC institutional review
195   board requirements (protocol METC-2012387). Skin biopsies were sampled before the study for
196   routine diagnostic purposes and used to isolate dermal fibroblasts using standard procedures.
197   Fibroblasts were tested negative for mycoplasma infection.
198
199   *Neuropathology*
200   An autopsy including brain was performed after demise of individual P1 at 14 days of age and
201   individual P10 at two days of age. The material was fixed in 4% formalin. Samples from frontal,
202   parietal, temporal, and occipital lobes, deep nuclei, cerebellum, brain stem and spinal cord were
203   submitted for histological evaluation. Paraffin-embedded samples were cut to a thickness of 5 μm
204   and hematoxylin and eosin-staining (H&E) or Lugol-PAS staining were performed according to the
205   manufacturer's guidelines (Hoffmann-LaRoche, Basel, Switzerland). For the age- and gender
206   matched control brain, the sample collection was approved by the Institutional Ethical Review Board
207   (EP02/21AG) of the Clinical Hospital Centre and School of Medicine, the University of Zagreb, in
208   accordance with the Helsinki declaration 2000, and became a part of the Zagreb Neuroembryological
209   Collection[25].
210
211   *Genomic and Transcriptomic analysis*
212   *Whole exome sequencing (WES)*
213   DNA was isolated from blood of the probands and family members and used for exome and Sanger
214   sequencing, in nine different laboratories. WES data are deposited internally at the Erasmus MC and
215   in each medical institute referring the individuals with *TMX2* variants, in respect to the privacy of the
216   families. Details of sequencing and analysis pipelines are described in the **Supplemental data**.
217
218   *RNA sequencing*
219   Skin fibroblasts from affected individuals P1, P2 and four different healthy age and sex (male)
220   matched controls were cultured to 80% confluence in T175 flasks, before RNA isolation with TRIzol™
221   Reagent (Invitrogen®, 15596026) and RNA cleanup with RNeasy mini kit (Qiagen®, 74106). The

NEBNext Ultra Directional RNA Library Prep Kit for Illumina was used to process the samples. Strand-specific mRNAseq libraries for the Illumina platform were generated with a poly-A selection and sequenced at GenomeScan (GenomeScan, Leiden, The Netherlands). Fastq files from forward and reverse reads were aligned to reference genome hg38 with the STAR aligner tool (v.2.4.2a)[26]. Counts per gene were calculated from bam files using the featureCount program with version 27 of the genecode hg38 annotation[27]. For differential gene expression P1 and P2's samples were compared to four male control samples in R (v.3.4.3) (R Core Team (2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria) using the edgeR package (v.3.20.9)[28]. Functional annotation clustering of the top 1000 differentially expressed genes (p<0.05) was performed with gene ontology Database for Annotation, Visualization and Integrated Discovery (DAVID, v6.8)[29; 30]. Downstream affected biological functions were determined with Ingenuity Pathway analysis (IPA, Qiagen®, vs.2018) on all differentially expressed genes with a p-value below 0.05.

qPCR

Skin fibroblasts were cultured in T75 culture flasks, in DMEM with 10% Fetal Calf Serum (FCS), 1% PenStrep, Lonza® (DMEM with serum), to 80% confluence. Total RNA was extracted on RNeasy mini columns (Qiagen®, 74106) according to the manufacturer's protocol. Reverse transcription was performed on 1 µg of RNA in a total volume of 20 µl, with the iScript cDNA Synthesis kit (Bio-Rad Laboratories®) used according to the manufacturer's instructions. Real time quantitative Polymerase Chain Reaction (RT-qPCR) was performed using iTaq™ Universal SYBR® Green Supermix (BioRad®) according to manufacturer's instructions. Primers for RT-qPCR analysis for the experiments shown in Fig. 3 are listed in Table S1.

Antibodies

Primary antibodies used: Polyclonal Rabbit anti-human TMX2 (HPA040282, Sigma®, WB 1:250), Monoclonal Rabbit anti-human HSP60 (D6F1, Cell Signaling®, Immunocytochemistry (ICC) dilution 1:800), Monoclonal Rabbit anti-human CNX (C5C9, Cell Signaling®, ICC 1:50, IP 1:1000), Mouse monoclonal anti-SERCA2 ATPase (ab2861, Abcam IP:1:1000), Mouse monoclonal anti-Myc (9B11, Cell Signaling Technologies®, WB 1:3000 and ICC 1:500), Mouse monoclonal anti-PDI (1D3, ADI-SPA-891, Enzo Life Sciences, WB: 1:1000)

Secondary antibodies used for ICC: Green Goat anti-Rabbit IgG (H+L) Alexa Fluor 488 (1:400, Thermo Fisher Scientific®, A11088), Red Cy™3 AffiniPure Donkey Anti-Mouse IgG (H+L) (1:100, Jackson Laboratories®, 715-165-150). Secondary antibodies used for WB in 1 in 10 000: Red IRDye® 680RD Goat anti-Rabbit IgG (H + L) (LI-COR Biosciences®, 926-68071), Green IRDye® 800CW Goat anti-Mouse IgG (H + L) (LI-COR Biosciences®, 926-32210).

Plasmid constructs

Wild-type human *TMX2* (NM_015959) was cloned in a pCMV-Entry-Myc-DDK TrueORF Gold vector (OriGene®, RC200032). 50 µL semi-competent homemade *Escherichia coli* XL10-Gold Bacteria strains were thawed on ice for 20 minutes and subsequently incubated for 15 minutes with 0.1 µg wild-type *TMX2* plasmid. Transformation of the bacterial cells was induced through a heat shock at 42°C for 2 minutes. 800 µL Luria-Bertani (LB) broth (EZ™ Mix, Lennox®) was added to the cells and placed under agitation (200 rpm, 40 min, 37°C). Selection of transformed cells was performed overnight on LB-Kanamycin agar plates at 37°C. Vector-positive colonies were grown to 50 mL midiprep. Plasmid DNA

266 was isolated with the Qiagen® Plasmid Plus Midi kit. The full length and sequence of *TMX2* cDNA in
267 the plasmid was checked by capillary sequencing before performing the transfections.
268 pcDNA™3.1/Myc-His (-)/LacZ (Thermo Fisher Scientific®) was used as a negative control and kindly
269 provided by Dr. Mark Nellist.
270
271 *Site-directed Mutagenesis (SDM)*
272 Variant *TMX2* constructs (TRX domain SNDC to SNDG p.Cys170Gly and affected individuals' variants
273 p.Arg53Cys and p.Arg231Trp) were generated according to manufacturers' procedures using the
274 QuikChange II XL Site-Directed Mutagenesis Kit (Agilent®), wild-type purified *TMX2* construct dilution
275 (10 ng/µL) and 100 ng/µL primers specified in Table S2. PCR products were transformed in
276 ultracompetent Escherichia coli XL10-Gold bacteria supplemented with β-mercaptoethanol in SOC
277 medium through a heat shock at 42°C for 30 seconds. Selection, midi isolation and Sanger
278 sequencing were performed in analogy with the wild-type construct.
279
280 *Sanger sequencing of plasmid DNA*
281 Sanger sequencing of wild-type and variant plasmid DNA was performed as earlier described[31].
282 Briefly, amplification reactions were performed in a total volume of 20 µl, containing 1× PCR buffer
283 with Mg (Roche), 200 µM of each dNTP, 1 µM forward and reverse primer (specified in Table S3), 0.1
284 units Fast Start Taq DNA polymerase (Roche), and 25 ng genomic DNA. PCR conditions were as
285 follows: 5' 96°C, 10 cycles of 30" 96°C, 30" 68°C (−1°C/cycle), 60" 72°C, followed by 25 cycles of 30"
286 96°C, 30" 58°C, 60" 72°C, and a final extension for 5' 72°C.
287 PCR reactions were purified with ExoSAP-IT (USB). Direct sequencing of both strands was performed
288 with Big Dye Terminator chemistry (version 3.1; Applied Biosystems). DNA fragment analysis was
289 performed with capillary electrophoresis on an ABI 3130 Genetic Analyzer (Applied Biosystems) with
290 the software package Seqscape (Applied Biosystems, version 2.1).
291
292 *Transfection*
293 Human Embryonic Kidney HEK293T cells were plated at $5x10^4$ cells/cm^2 with or without 24 mm cover
294 slips (Thermo Fisher Scientific®) cultured in 2mL DMEM with serum in a 6 well plate or 10 cm petri
295 dishes for immunoprecipitation. The next day culture media was replaced with 2 mL DMEM without
296 serum (Lonza®). Per 10 cm^2, 1 µg plasmid DNA was added to 125 µL DMEM without serum at room
297 temperature and 3 µL/10cm^2 Lipofectamine™ 2000 Transfection Reagent (Thermo Fisher Scientific®)
298 was added to 125 µL DMEM without serum. These tubes mixed and incubated 5 minutes at room
299 temperature, prior to transfection. The appropriate volume was added to each dish in a dropwise
300 manner. After 3 hours, 10% FCS and 1% PenStrep was supplemented to the dishes. After 24h
301 transfection, cells were fixated with methanol for 10 minutes at -20°C or lysed for western blot and
302 immunoprecipitation. Transfection was also stable after 48 and 72h (Fig.S3).
303
304 *Immunoprecipitation (IP) and Mass spectrometry (MS)*
305 Exogenous TMX2 was immunoprecipitated after transfection in HEK293T cells. Initially, 15 µL EZview
306 Red Anti-c-Myc Affinity Gel beads (E6654, Sigma Aldrich®) were washed with non-denaturing TNE-
307 1% lysis buffer (50mM Tris pH 7.6 + 100mM NaCl + 50mM NaF + 1% NP-40 + 1mM EDTA + Protease
308 inhibitor tab Roche®). TMX2-transfected and control Lac-Myc-transfected HEK293T cells in 10 cm
309 Petri's dishes were transferred on ice, washed with 1×dPBS, and lysed with 800 µL TNE-1% lysis
310 buffer. To test transfection efficiency and localization, each dish contained a 24 mm coverslip, which

was subsequently fixated and immunostained, before adding the lysis buffer. Lysates were incubated on ice for 10 minutes and centrifuged at 10000 x g for 10 minutes at 4°C. The supernatant was added to the washed beads and incubated overnight under agitation at 4°C. After washing 3 times with TNE-1% lysis buffer and centrifugation at 1000 x g, 15 sec, 4°C, bead pellets were subjected to a Mass spectrometry preparation as described[32]. Protein Mascot scores and numbers of unique peptides were taken directly from the Mascot output and reported. Only hits with a Mascot score higher than 40 were taken into account for analysis.

Mitochondrial respiration and glycolysis determination

Bioenergetics profiles of human primary skin fibroblasts were generated in real time with a Seahorse XF24 Extracellular Flux Analyzer (Agilent Technologies, Santa Clara, Ca, USA) as previously described[33]. Fibroblasts were seeded on a Seahorse XF-24 plate at a density of 6×10^4 cells per well and grown overnight in DMEM with serum at 37 ˚C, 5% CO_2. This density ensures a proportional response to the uncoupler FCCP (Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone) with cell number and resulted in confluent cultures, in which cell replication was further prevented by contact inhibition. On the experimental day, medium was changed to unbuffered DMEM (XF Assay Medium – Agilent Technologies, Santa Clara, Ca, USA) supplemented with 5 mM glucose and 1 mM sodium pyruvate, and incubated 1 hour at 37 °C in the absence of CO_2. Medium and reagent acidity was adjusted to pH 7.4 on the day of the assay, according to manufacturer's procedure. Mitochondrial respiration was measured as the oxygen consumption rate (OCR), and glycolysis was measured as the extracellular acidification rate (ECAR). After three baseline measurements for the oxygen consumption ratio (OCR), cells were sequentially challenged with injections of mitochondrial toxins: 0.5 µM oligomycin (ATP synthase inhibitor), 1 µM FCCP (mitochondrial respiration uncoupler), 0.5 µM rotenone (complex I inhibitor), and 0.5 µM antimycin (complex III inhibitor). For galactose experiments, cells were cultured in galactose 10 mM, 10% FCS, 2 mM glutamine, 5 mM Hepes and 1% penicillin-streptomycin medium for three days before the bioenergetics assay[33].

A minimum of two Seahorse replicates were performed for each fibroblast line. In each replicate, we used six wells for each line. In each run, six wells were always used for a reference primary fibroblast line with highly characterized bioenergetics behavior. Three reference lines that were available at the Erasmus MC institute have been used[33].

Basal respiration was defined as the average OCR values at baseline. Respiration dedicated to ATP production was calculated as difference between basal respiration and the respiration measured after oligomycin injection. Reserve capacity was calculated as the difference between the maximal respiration (the average OCR of the three measurements following the FCCP injection) and basal respiration. The rotenone dependent respiration parameter was calculated as the difference between the maximal respiration value and the average OCR values obtained after the rotenone injection and was used to evaluate the activity of mitochondrial complex I. Basal glycolysis was defined as the average of the 3 baseline ECAR measurements, and the increase in glycolysis after blocking ATP synthase was indicated as oligomycin stimulated glycolysis.

TMX2 Redox state assay

HEK293T cells were transfected during 24 hours with plasmid DNA producing Myc-tagged β-lactamase control protein (Lac-Myc), wild-type (TMX2) or variant TMX2 (p.Cys170Gly, p.Arg53Cys and p.Arg231Trp) in a 6 well plate. Afterwards cells were treated with different ER-stress inducers or oxidant/reductant at 37°C with 5% CO2, according to Matsuo et al [34]: 6h with 0,5 µg/mL Brefeldin A

355 (BFA; Cayman Chemical® CAS 20350-15-6, 20 mg/mL stock in DMSO), 6h with 5 µM Thapsigargin (TG,
356 Sigma® T9033, 1mM stock in DMSO), 6h with 10 µg/mL Tunicamycin (TM, Sigma® T7765, 1mg/mL
357 stock in DMSO), 10 minutes with 5 mM DL-Dithiothreitol (DTT, Fluka® CAS 3483-12-3, 100 mM stock
358 in MilliQ sterile water), or 10 minutes with 200 µM Hydrogen peroxide H_2O_2 (Merck®, 822287). Free
359 thiol groups were alkylated by washing and 10 min incubating the cells with ice-cold 1× dPBS (Sigma
360 Aldrich®) supplemented with 20 mM N-ethylmaleimide (NEM, Sigma®, E3876-5G) and 4× Laemmli
361 buffer (3:1) before storage at -20°C. Total protein concentrations were determined by a BCA
362 protocol with Varioskan™ LUX multimode microplate reader (Thermo Fisher Scientific®). Equal
363 protein concentrations were loaded onto a 4-15% Criterion™ TGX Stain-Free™ Protein Gel (Bio-Rad
364 Laboratories®). Proteins were separated in a non-reducing SDS-PAGE with a Criterion™ Cell geltank
365 (Bio-Rad Laboratories®) at 100 Volt for 1h40min in Tris-Glycine-SDS running buffer. Proteins were
366 transferred by wet blotting to a Nitrocellulose membrane (Amersham Protran 0.45 NC, GE
367 Healthcare Life Sciences®) at 100 Volt for 1h at 4°C or alternatively on a Trans-Blot Turbo 0.2 µm
368 Nitrocellulose membrane (BioRad®) at 25V, 1.5A for 20 minutes in a Trans-Blot Turbo transfer
369 system (BioRad®). After antibody incubation, bands were detected with a fluorescent based
370 approach on the Odyssey Infrared Imager (LI-COR Biosciences®). Densitometry analysis to determine
371 Dimer/monomer ratios was performed in Odyssey 3.0 Software or Image Studio Lite Version 5.2.

372 *Statistics*
373 Statistical tests were performed with GraphPad 8 and are specified in legends of the experiments.
374
375 **RESULTS**
376 **Clinical overview**
377 The clinical features observed in all fourteen individuals, in whom we detected *TMX2* variants, have
378 been summarized in **Table 1** and full clinical and MRI description is available in the Supplemental
379 Note, **Table S4** and **Figure 1**. Most subjects (11/14) were reported with microcephaly (defined as
380 OFC at or below -2.5 SD, for age and sex; **Table 1**) and, where documented, this was present at birth
381 or at the first clinical examination. However, intra-familial discrepancy is present, because only one
382 of the two siblings of family 5 was microcephalic at adult age (P5), while the other sibling has a
383 borderline normal head circumference (P4) in the third decade of life. Two other affected
384 individuals of family 9 and 10 did not present with microcephaly at the last examination (**Table 1**,
385 P13 and P14). With the exclusion of two individuals (P6 and P14), all have suffered from drug-
386 resistant epilepsy, occurring in most cases in early infancy, characterized by apnea, epileptic spasms,
387 myoclonic seizures, focal seizures with or without secondary generalization, generalized tonic clonic
388 (GTC) seizures and in one case possible diaphragmatic myoclonia. Three affected individuals of the
389 cohort died during infancy, two of them of severe epilepsy in the early post-natal period. The brain
390 imaging of these two is strikingly similar (**Figure 1**, P1 and P10) and resembles a congenital viral
391 (CMV) infection for the presence, besides diffuse bilateral polymicrogyria (PMG), of reduced central
392 white matter volume, abnormal appearance of the periventricular borders with an occipital
393 pseudocyst. In both cases no infection was documented, and brain pathology excluded the presence
394 of inflammatory signs. All subjects, but one (Family 10, P14) surviving beyond infancy present with
395 severe developmental delay (**Table 1**), progressing to profound intellectual disability, cerebral palsy
396 with absent ambulation and lack of speech and/or progressive neurodegenerative course. No
397 additional extra-CNS malformations or health issues were observed, except for expected
398 complications of the underlying brain pathology. Metabolic screening performed in most subjects

399 did not reveal abnormalities of intermediate or energy metabolism. Two individuals have been
400 followed in their third decade (P4 and P5): they both showed signs of regression, with loss of motor
401 skills and severely impaired cognitive skills and no speech development.

402 Structural brain abnormalities were detected in almost all the subjects undergoing MRI scan. In
403 seven of the twelve affected individuals who received an MRI scan (**Figure 1**) a cortical malformation
404 has been documented. Diffuse PMG (small and excessive number of gyri) was observed in five
405 individuals (**Figure 1**, P1, P2, P3, P10 and P12), while the two siblings from family 5 show diffuse
406 pachygyric (= thickened and smooth) cortex (**Figure 1**, P6-P7). The brain imaging of these latter
407 siblings had been reported in supplemental data from a cohort of undiagnosed individuals with
408 malformations of cortical development[24]. In three other individuals brain imaging shows
409 (progressive) global cerebral atrophy (families 4 and 6). The two remaining affected individuals
410 showed an MRI with no cortical malformation (P14) or a hemihypertrophy with frontal dysgyria
411 (P13). No brain imaging was performed in individual P8 (Family 6) and individual P11 (Family 8).

412 **Brain pathology of affected individuals (P1 and P10)**
413 At autopsy of individual P1 (day 14 postpartum), the head circumference was 34 cm (-2SD) and the
414 brain weight 316 g (normal weight at term: 400-450 g). Macroscopically, the brain surface was
415 polymicrogyric with the temporal regions being least affected (**Figure 2A and 2B**).
416 Evaluation of H&E stained sections of the frontal, parietal, temporal and occipital cortex showed
417 extensive unlayered polymicrogyria throughout the sampled cortical sections (**Figure 2E and 2F**).
418 Undulating bands of neurons extended deeply in the cortex. The insular and parahippocampal region
419 were least affected with undulating neuronal bands extending less deep into the cortex. The
420 hippocampus was spared. The transition from normal cortex to polymicrogyric cortex was abrupt.
421 The molecular layer appeared fused between adjacent gyri causing inclusions of pial vessels in the
422 deep cortical region. Leptomeninges overlying the polymicrogyric cortex were focally thickened.
423 Overmigration of neurons into the arachnoid space was not noted. The grey-white matter junction
424 was blurred under affected cortical areas. The white matter was normal. Heterotopic remnants of
425 the germinal matrix were occasionally observed in the periventricular region which is considered
426 pathologic given that the affected individual was born at term. Telangiectatic vessels were present in
427 the brain stem at the level of the locus coeruleus. Histologically, other brain structures and the eyes,
428 especially the retina appeared normal. There were no signs of mitochondrial disease or an acquired
429 cause for the malformation, e.g. no calcifications or inflammatory cells. The basal ganglia were
430 normal as well as the cerebellum, which consisted of a four-layered cortex including the for the age
431 appropriate external granular layer.

432 Brain examination of individual P10 (**Figure 2C**) macroscopically showed a polymicrogyric cortex of
433 the occipital lobes, but microscopically the whole cerebral cortex was polymicrogyric, with diffuse
434 dyslamination, fusion of molecular layers and blurred grey-white matter junction (**Figure 2G**). In
435 contrast with P1, in the polymicrogyric areas glioneuronal heterotopia were diffusely seen migrating
436 over the meninges in P10's brain. In the frontal area few calcifications were seen at the grey-white
437 matter border, with some calcification of the pericallosal artery, without any other evidence for
438 (focal) infection or inflammation. The occipital ependymal layer showed interruptions and gliotic
439 changes with some reactive macrophages. The presence of neuroglial cells migrating over the glia
440 limitans of the pia into the arachnoid space is typical of the cobblestone malformation. However,

441 there were no additional abnormalities common in the cobblestone malformation, such as
442 brainstem and cerebellar hypoplasia[35].
443

444 **Genomic and Transcriptomic analysis**
445 Biallelic variants in *TMX2* were identified in fourteen affected individuals from ten unrelated
446 pedigrees by whole exome sequencing (WES), compatible with autosomal recessive inheritance.
447 Detailed information on the genomic alterations (cDNA alteration, protein alteration, gnomAD
448 frequency, SIFT, MutationTaster and CADD scores) are described in **Table S4** and **Supplemental**
449 **Results** and a schematic overview of the gene and the thirteen discovered variants can be found in
450 **Figure 3A**. *TMX2* encodes a transcript of 8 exons (NM_015959.3), which is translated into a protein
451 with 296 amino acids. To test the effect of each variant on *TMX2* mRNA expression transcriptomic
452 analysis was performed.   RT-qPCR in skin fibroblasts from the affected newborn **P1** of **Family 1** with
453 a compound heterozygous mutation in *TMX2* (c.164A>C, p.Asp55Ala; c.391dup, p.Leu131Profs*6),
454 showed that *TMX2* mRNA expression was much lower (nearly half fold), compared to healthy
455 controls (**Figure 3 B)**. To determine which of the alleles was still expressed, we performed allele
456 specific RT-qPCR (primers specified in **Table S1)**. Results showed that the allele carrying the
457 frameshift in exon 4 barely expressed any product (2-3% of total level *TMX2* mRNA in healthy
458 controls), indicating that very likely the transcript is subjected to nonsense mediated decay (NMD)
459 (**Figure 3C**). When amplifying the other allele, total *TMX2* mRNA expression was again reduced to
460 approximately half, confirming our previous result (**Figure 3B)** and showing that the allele with the
461 c.164A>C, p.Asp55Ala variant is normally expressed (**Figure 3C**).

462 In **Family 2**, the proband (**P2**) had a homozygous *TMX2* missense change in the ultimate nucleotide
463 of exon 6 (c.614G>A, p.Arg205Gln), with a predicted effect on splicing. RT-qPCR did not show
464 significant decrease in expression of *TMX2* mRNA in skin fibroblasts from the proband, compared to
465 healthy controls (**Figure 3B**). However, since the variant affected the last nucleotide of an exon, an
466 effect on mRNA splicing was suspected. We used RNAseq in combination with Integrated Genomics
467 Viewer (IGV) to visualize cumulative transcript reads per exon in a Sashimi plot (**Figure 3D**) and the
468 amount of reads per million were calculated (**Figure 3E**). The c.614G>A, p.Arg205Gln variant indeed
469 affected splicing through introduction of a new internal splice site in exon 6, resulting into four
470 different transcripts: regular mRNA, an alternative transcript with a loss of 11 nucleotides within
471 exon 6, an alternative transcript with full in-frame exon 6 skipping (loss of 66 nucleotides) and mRNA
472 with intron 6 retention (**Figure 3E**). This latter transcript is also present at low level in healthy
473 controls. Individual reads of each transcript are shown in **Figure S1**.

474 In **Family 3**, individual P3, similar to the variants in individual P1, a combination was found of a
475 missense change in exon 1 (c.157C>T, p.Arg53Cys, nearby the p.Asp55Ala of P1, together with a
476 nonsense variant leading to a premature stop codon in the last exon of *TMX2* (c.757C>T, p.Arg253*).
477 The effect of the variants on *TMX2* transcription in skin fibroblasts was tested. RT-qPCR showed a
478 mean decreased level of *TMX2* mRNA expression by 23%, potentially indicating that the premature
479 termination codon in the last exon of the transcript partially escapes nonsense mediated decay, as
480 being less than 50 to 55 nucleotides from the stop codon at the 3'-end (for TMX2 nt836-891) (**Figure**
481 **3B**)[36].

482 For families 4 to 10 no materials were available to test the transcriptional effect of each variant.
483 However, considering lethality in *Tmx2* null mice, residual *TMX2* transcript can be anticipated
484 originating from the missense alleles and/ or the allele creating a new splice acceptor site (P10).

485 **Gene ontology (GO) analysis of differentially expressed genes in *TMX2* pathogenic variants**
486 Our data clearly indicates that biallelic *TMX2* variants lead to reduced *TMX2* expression, acting as
487 loss of function variants (LoF) (**Figure 3**). Compared to other TMX family members, only *TMX2* is
488 expressed steadily from week 8 throughout fetal brain development, even increasing during
489 postnatal life (mRNA expression during human brain development retrieved from Allen human brain
490 atlas **Figure S3**). We therefore considered the *TMX2* variants as probably explanatory for the early
491 neurological manifestation and decided to investigate their effect in detail.
492 We performed analysis of RNAseq data from cultured skin fibroblasts of two affected individuals (P1
493 and P2), in parallel with three age and gender matched controls, and studied which pathways were
494 deregulated.

495 *Functional annotation clustering analysis*
496 Functional annotation clustering analysis of the top 1000 significant differentially expressed genes
497 (DEGs) (p<0.05), by the Database for Annotation, Visualization and Integrated Discovery (DAVID,
498 v6.8) ranked the top cluster of genes as those associated with post-translational modifications, i.e.
499 intramolecular or intermolecular disulfide bond formation (Annotation Cluster 1: Disulfide bond p =
500 9.9×10^{-24}) and N-linked glycosylation (Annotation Cluster 1: Glycoprotein p= 2.1×10^{-28} and
501 Glycosylation site:N-linked p=2.5×10^{-27}) (**Figure 4A**). From this cluster of genes, 24 disulfide
502 containing genes were subtracted as being the highest deregulated of this cluster in cells from
503 affected individuals, having a False Discovery Rate (FDR) lower than 0.05 (**Figure 4B**). Stringent
504 filtering (FDR<0.01) without clustering, uncovered 37 differentially expressed genes of which five
505 were indirectly controlled by the UPR or regulate expression of UPR markers, i.e. *CXCL5* (OMIM
506 600324) [37], *DAPK1* (OMIM 600831) [38], *HGF* (OMIM 142409) [39], *LTBP1* (OMIM 150390) [40] and *CES1*
507 (OMIM 114835) [41]. Interestingly, the second highest deregulated gene *LTBP1* encodes a known
508 folding substrate for another PDI protein, ERp46, also known as TXNDC5[42; 43]. Although it has been
509 suggested that most PDIs show substrate specificity[2], LTBP1 could also be a substrate of TMX2 or
510 TMX2 might affect TXNDC5 mediated folding.
511 The second most significant functional annotation cluster ranks genes having a transmembrane
512 domain (Enrichment score= 9.43) and a third most significant cluster contains genes encoding
513 proteins involved in synaptic function, specifically located at the postsynaptic membrane
514 (Enrichment Score= 4.63). This latter membrane is enriched with receptors and ion channels,
515 essential for the interaction with neurotransmitters. Interestingly, another cluster mentions the
516 deregulation of calcium ion binding (Annotation Cluster 6 Enrichment score 3.16).
517
518 *Ingenuity pathway analysis (IPA)*
519 Ingenuity pathway analysis (IPA) of the same differentially expressed genes in cells from the two
520 probands (p<0.05), taking into account the logarithmic Fold Change (LogFC) of each gene, was used
521 to calculate the most affected biological functions and diseases networks (**Figure 4C**). Only activation
522 Z-scores in the 90 percent confidence interval were considered to be significant (Z[$-\infty$,-1.65] and
523 Z[1.65, $+\infty$]). Interestingly, this analysis showed two key IPA categories being inhibited in *TMX2*
524 affected individuals, i.e. 'Nervous System Development and Function' and 'Cellular Growth,
525 Proliferation and Survival' (Blue bars in **Figure 4C**). The most significant inhibited function was

526 'quantity of neurons' (Z=-2.864), with a decreased outgrowth of cells (Z= -2.818), specifically neurons
527 (Z=-2.594) and neurites (Z= -2.46), all related to processes affected in microcephaly. Consequently,
528 transcripts related to learning ability (Z= -2.356) and cognition function (Z= -2.257) were also shown
529 to be potentially decreased in cells from affected individuals. Moreover, besides the development of
530 neurons (Z= -1.955), the differentiation of neurons was highly inhibited(Z= -1.812). Lastly, overall cell
531 survival (Z= -1.785) and viability (Z= -2.016) were decreased. When looking at the most activated
532 biological functions or associated diseases, seizures (Z=2.712) and seizure disorder (Z=2.819) are the
533 most significant activated features (Red bars in **Figure 4C**).

534 **Proteomics analysis of exogenous TMX2**
535 In view of the effect of *TMX2* variants on transcriptome, specifically on disulfide bond formation, we
536 wondered whether TMX2 functions as an oxidoreductase and/or chaperone in protein folding. A
537 transfection protocol was optimized in HEK293T cells with a Myc-tagged vector containing full length
538 *TMX2* sequence (p.CMV6.TMX2-Myc/DKK) and a Myc-tagged β-lactamase vector as negative control
539 (pcDNA™3.1/Myc-His (-)/LacZ). Immunocytochemistry of exogenous TMX2 localized the protein to
540 the MAM through co-localization with the marker Calnexin (CNX) (**Figure S4 A**) and in the vicinity of
541 the mitochondria, visualized by mitochondrial marker HSP60 (**Figure S4 B**). Next, we aimed at the
542 identification of the TMX2 interacting proteins, by performing mass spectrometry-based proteomics
543 of co-precipitated proteins. A 24-hour over-expression of Myc-tagged *TMX2*, followed by
544 immunoprecipitation and LC-MS/MS reveals 71 unique peptides as putative interactors. The list of
545 reproducible co-precipitated proteins is shown in **Table S5** and visualized with Cytoscape String App
546 according to pathway involvement in **Figure 5A**. A first interesting observation was that TMX2
547 physically interacts with MAM marker CNX, which is a calcium-binding protein folding chaperone.
548 Other PDIs have also been shown to bind with CNX, e.g. TMX1[2], TMX4[6], ERp57[2]. Binding was
549 reciprocally confirmed after IP of CNX and detection of Myc-tagged TMX2 on western blots (**Figure
550 5B**). Besides CNX, multiple other protein folding regulators and ER chaperones were interacting with
551 TMX2 (**Figure 5, dark blue**), i.e. co-chaperones of the HSP70 family DNAJA2(HSP40) and BCL2
552 associated athanogene 2(BAG2), chaperonin containing TCP1 subunit 5 (CCT5), Translocon-
553 associated protein/TRAP subunit alpha (SSR1), N-glycosylation regulators glucosidase II alpha subunit
554 (GANAB) and Dolichyl-diphospho-oligosaccharide-protein glycosyltransferase complex (OST
555 complex: RPN2, DDOST, STT3B, MLEC)[44].

556

557 Furthermore, besides CNX, TMX2 bound with other key-regulators of calcium homeostasis, i.e. Ca^{2+}-
558 binding proteins (RCN2, HAX1, SSR1) and Ca^{2+}-ion channels located at the MAM or mitochondrial
559 membrane (ATP2A2/SERCA2, VDAC1) (**Figure 5A, light blue**). TMX2 also binds to Erlin-2 which
560 directly regulates inositol 1,4,5-trisphosphate Ca^{2+} receptor degradation. These calcium receptors
561 and channels are necessary for mitochondrial bioenergetics. SERCA2, like CNX, is a main interactor of
562 some PDI members (TMX1[7], ERdj5[1]) and described as a key regulator of protein folding. Binding was
563 confirmed reciprocally after immunoprecipitation of SERCA2 and detection of Myc-tagged TMX2 on
564 western blot (**Figure 5B).** Proteomics data also indicates physical interaction of TMX2 with
565 components of mitochondrial outer and inner membrane complexes (**Figure 5A, green**), e.g. the
566 mitochondrial contact site and cristae organizing system (MICOS, MIC60/IMMT subunit), the
567 mitochondrial precursor protein import pathways (TOM22 and TIM23 complex)[45], and the
568 mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I NDUFA2 and NDUFA12
569 subunits).

570 TMX2 also interacted with proteins regulating the unfolded protein response, i.e. DDRGK1, a direct
571 regulator of IRE1α-XBP1 and PERK-eIF2α-CHOP signaling[46], or the UPR associated endoplasmic
572 reticulum-associated degradation (ERAD), dependent on an ubiquitin-proteasome system (UPS)
573 (**Figure 5, red**), i.e. TMX2 binds with VCP-AMFR ERAD complex, Erlin-2 involved in ERAD of IP3Rs,
574 Ubiquitin-binding protein UBXN1, deubiquitinating enzyme USP25, and proteasome subunits
575 PSMD2, PSMD3 and PSMA5. Because of these interactions, the RNAseq showing dysregulated genes
576 indirectly linked to UPR signaling and the role of TMX2 in protein folding, we tested the hypothesis
577 whether *TMX2* variants activated the UPR, specifically the IRE1α-XBP1 and PERK-eIF2α-CHOP
578 signaling. RT-qPCR of UPR downstream mRNA markers *CHOP* and spliced *XBP1* was performed for
579 the three available fibroblasts lines derived from affected individuals and showed that aberrant
580 TMX2 did not affect the amount of expressed s*XPB1*, nor *CHOP* (**data not shown**). Although the
581 RNAseq data of affected individuals showed DEGs indirectly linked to the UPR, no direct factors of
582 any of the three UPR pathways were found to be upregulated when *TMX2* was mutated. Hence,
583 together these data indicate that*TMX2* pathogenic variants do not lead to constitutive UPR
584 activation in fibroblasts from affected individuals.
585
586 **Mitochondrial bioenergetics in *TMX2* variant fibroblasts**
587 PDIs and protein folding are important determinants for normal mitochondrial bioenergetics and cell
588 survival. In view of the putative function of TMX2 at the ER-MAM-mitochondria interface, the results
589 of RNAseq (hinting towards a deregulated disulfide bond formation and calcium binding in cells from
590 affected individuals) and proteomics analysis (showing binding with regulators of protein folding,
591 ERAD, ER-mitochondrial UPR and Calcium homeostasis), we focused on mitochondrial activity and
592 evaluated mitochondrial respiration and glycolytic activity in *TMX2* variant fibroblasts derived from
593 three affected individuals (P1, P2 and P3) using a Seahorse Extracellular Flux Analyzer. Only P3
594 showed reduced basal mitochondrial activity and reduced respiration dedicated to ATP production
595 when compared to healthy control lines. At the same time, all *TMX2* variant fibroblasts featured
596 suppressed mitochondrial respiration upon stimulation with the mitochondrial uncoupler FCCP, with
597 a significantly reduced reserve capacity – which reflects the bioenergetics reservoir available to
598 counteract cellular stress - and overall decreased rotenone dependent respiration. The latter
599 indicates a reduced activity of mitochondrial complex I (**Figure 6A and 6C**). Interestingly, P1 and P2,
600 but not P3 showed a significant increase in the glycolytic activity – that was measured as lactate
601 dehydrogenase mediated acidification of the medium- both in basal condition and upon stimulation
602 with the mitochondrial ATP-synthase inhibitor oligomycin (**Figure 6B and 6D**), indicating that *TMX2*
603 variant fibroblasts compensated the mitochondrial bioenergetics defects by potentiating the
604 glycolytic pathway and glucose catabolism. Quantification of cellular ATP levels showed no
605 differences between *TMX2* affected individuals and controls (**Figure S5**). To identify potential
606 mitochondrial defects silenced in glycolysis permitting conditions, we performed the experiments
607 also in conditions where glycolysis was inhibited by the presence of galactose, forcing cells to rely on
608 mitochondrial respiration for ATP production. As expected, P1 and P2 failed to potentiate basal
609 respiration and showed no significant increase of respiration dedicated to ATP production and of
610 mitochondrial complex I activity when cultured in galactose medium, although retained the ability to
611 potentiate the reserve capacity (**Figure 6E**).
612
613 **Redox state analysis of wild-type and variant TMX2**
614 *TMX2 oxidizes and reduces in native conditions*

We tested whether thiol groups in TMX2 can be oxidized and reduced and thus whether TMX2 is able to form disulfides, hence would be able to influence protein folding. HEK293T cells were transiently transfected with *TMX2* (**Figure 7A**) or β-lactamase vector (**Figure 7B**) and the redox state of TMX2 was monitored before and after treatment with the reducing agent DTT, the oxidant hydrogen peroxide (H_2O_2) or the ER-stress inducers: Brefeldin A (ER-Golgi transport blocker) (**Figure 7 A-B**), Thapsigargin (SERCA2 inhibitor) or Tunicamycin (N-glycosylation inhibitor) (**Figure 7C**). To be able to distinguish redox state of cysteines, cells were incubated with a cysteine alkylating reagent N-ethylmaleimide (NEM) to covalently bind reduced thiol groups (+0.125kDa /thiol), but not oxidized disulfide groups. **Figure 7A,** lane 1 and 5, shows that TMX2 exists in both a reduced NEM alkylated form (~33 kDa) and an oxidized lower molecular form (~31 kDa) in native conditions. These two bands were consistently found in all of our repeat experiments with the ratios of oxidized and reduced TMX2 alternating, e.g. sometimes more reduced TMX2 (**Figure 7A, lane 1**), sometimes equal amount (**Figure 7C, lane 1),** and sometimes more oxidized TMX2. ER stress induced by BFA, tunicamycin or thapsigargin did not alter TMX2 redox state (**Figure 7A, lane 2, 6 and Figure 7C lane 2, 5, 6**) nor its' protein level. DTT treatment partially shifted redox state to a more reduced TMX2 (**Figure 7A, lane 3**) and TMX2 was completely reduced in the presence of β-mercaptoethanol (**Figure 5B and S6**), indicating that at least part of TMX2 redox state is thiol mediated.

TMX2 dimerizes and oxidative stress elevates dimer/monomer ratio

Surprisingly, H_2O_2-mediated oxidation of cells overexpressing TMX2 did not result in an increase of the lower oxidized TMX2 band, as we observed for PDI (PDIA1) (**Figure 7A, lane 12**), but generated an intense TMX2-reactive extra band with higher molecular mass on immunoblot (**Figure 7A, lane 4 and 8;** apparent mass ~65kDa). Since molecular mass was double the amount of a TMX2 monomer, we hypothesize that this band represents a slower migrating homodimer. Dimer/monomer ratios were calculated, showing up to a 200 fold increase of dimerization in oxidative environment (**Figure 7D,** H_2O_2 p=0.0005). The dimer was still present when SDS-PAGE was performed in reducing conditions with β-mercaptoethanol and without NEM, although the ratio dimer/monomer was almost inverted and the monomer represented the major band (**Figure S6**). These results indicated that oxidative conditions mediated by H_2O_2, induce dimerization of TMX2 and that this dimerization is at least partially mediated by disulfide bond formation. Homodimerization was confirmed through linear correlation between the observed molecular weight on blot (average 57.8kDa, n=18) and the calculated expected molecular weight with the method of Lambin for a gradient SDS-PAGE gel (4-15%) (**Figure S7**)[47].

TMX2 variants highly dimerize and polymerize in native and ER-stress conditions

We tested the effect of variants on the behavior of exogenously expressed TMX2. By in vitro mutagenesis, the single cysteine in the atypical thioredoxin domain was substituted with a glycine, p.Cys170Gly. Interestingly, ablation of the active cysteine in the TRX domain still permitted dimerization, which supports the hypothesis that this dimer is not a mixed disulfide dimer of the TRX domain with another substrate. Moreover, dimerization of TMX2 was appreciated in the TRX domain variant, even under native conditions, i.e. independently of an oxidative stress, suggesting that this domain is involved in the reversibility of the TMX2 state between monomer and dimer (**Figure 7E**). Furthermore, oxidative stress even induced the formation of higher molecular weight polymers in the TRX domain mutant (**Figure 7C,** lane 10). To determine redox state of human *TMX2* pathogenic variants under different stress conditions, we overexpressed either a *TMX2* variant located in the

659   cytosolic domain, p.Arg53Cys , or a variant in the ER lumen domain, p.Arg231Trp (**Figure 7C, lanes**
660   **13-18, 19-24**). Strikingly, the amount of TMX2 dimer was significantly higher compared to wild-type
661   TMX2 for both variants in both native and under all stress conditions, not only H_2O_2, as quantified in
662   **Figure 7 E**. Dimer/ monomer ratios were increased by 10-fold (1:1), while in wild-type TMX2 this is
663   0.1:1, showing that the pathogenic variants block the protein in a dimerized state and that affected
664   individuals may have less monomeric protein available (**Figure 7 E**). Moreover, TMX2 with the
665   natural variants also displayed higher levels of polymerization, as seen in the TRX mutant (apparent
666   mass ~110kDa and 140kDa, observed average mass 97.1kDa and 138.9kDa with method of Lambin in
667   n=11). Based on the linear correlation between observed and expected mass, these bands seem to
668   represent homotrimers and tetramers of TMX2(**Figure S7**). Although the amount of dimer to
669   monomer ratios under oxidative stress was also doubled or tripled in mutant p.Arg231Trp or
670   p.Arg53Cys TMX2 compared to wild-type TMX2, the difference was no longer significant (**Figure 7E,**
671   **H_2O_2,, fourth graph**). DTT treatment prevented polymerization of the variants almost completely,
672   confirming that polymerization is (at least partially) mediated by disulfide bridge formation (**Figure**
673   **7E, third graph and Figure S6**). Notably, in vitro mutagenized Myc-tagged TMX2 was still able to bind
674   both CNX and SERCA2 (**Figure S8**).

675 **DISCUSSION**
676 We describe a disorder, characterized by developmental delay, microcephaly, impaired speech and
677 ambulation, epilepsy and cortical malformations, with a relatively wide spectrum of severity ranging
678 from early death to intellectual disability with mild motor impairment, resulting from recessive
679 *TMX2* variants.
680 Redox regulatory proteins are enriched at the MAM of the smooth ER [10; 48]. Some of these proteins
681 interact with ER calcium handling proteins and regulate the calcium flux into the mitochondria,
682 which, in turn, influences mitochondrial membrane potential and mitochondrial respiration[1].
683 Thioredoxins of the PDI family regulate the cellular redox state through oxidoreductase activity-
684 mediated disulfide bond formation and contribute to protein folding. The PDI transmembrane ER
685 thioredoxin-related (TMX) proteins, such as MAM-associated TMX1, seem to have dual function: on
686 the one hand in regulating protein folding, maintaining the redox environment of the ER and hereby
687 preventing ER stress, on the other hand in regulating calcium flux in the mitochondria[7]. Besides
688 regulating protein folding and calcium transport, thioredoxins in general are key molecules in the
689 regulation of oxidative stress through scavenging reactive oxygen species (ROS), such as hydrogen
690 peroxide[49].
691 TMX2 lacks the canonical oxidoreductase active C-X-X-C domain. However, its function as folding
692 chaperone is suggested by our data, demonstrating (1) the dysregulation of disulfide bond and N-
693 glycosylation-related genes in *TMX2*-deficient fibroblasts, (2) the interaction of TMX2 with several
694 proteins regulating protein folding and UPR and (3) the presence of both oxidized and reduced forms
695 in the maleimide alkylation assay. In addition, our mechanistic studies discover the function of TMX2
696 as regulator of calcium homeostasis and mitochondrial bioenergetics. TMX2 localizes at the MAM
697 where it physically binds to calnexin and SERCA2, whereas *TMX2*-variant fibroblasts show decreased
698 mitochondrial reserve capacity and lower ability to cope with oxidative stress, probably related to
699 defective calcium flux, similarly to what was proposed for *TMX1*-deficient cells[7]. Compared to *TMX*1,
700 *TMX2* is highly expressed in fetal and post-natal brain. The specific *TMX2* expression in the cortex
701 during prenatal life, together with the deleterious effect of its loss of function for human cortical
702 development, places TMX2 as a key molecule in the ER-mitochondrial redox regulation of brain

development. Although pathogenic variants in mitochondrial oxidoreductases and MAM-associated proteins have been reported as causes of pediatric neurologic disorders[16-20], the TMX2 related disorder is a malformation of cortical development resulting from a defect in a member of the PDI family.

TMX2 is thus an important regulator of oxidative stimuli and an intriguing aspect is its responsiveness to H_2O_2. The sensitivity of TMX proteins to H_2O_2 has received little attention, although it has been shown that their redox state dramatically changes after H_2O_2-treatment, as it happens for example for TMX4[6]. The hydrogen peroxide signaling molecule has long been considered as deleterious for cellular function and as a byproduct of oxidoreductase reactions, being rapidly metabolized by catalases, glutathione-peroxidases or peroxi-redoxins[49]. However, more recent findings highlighted the role of H_2O_2 as physiological regulator of redox signaling (oxidative eustress), acting via reversible cysteine and methionine oxidation[50]. Additionally, H_2O_2 functions in higher concentrations as a mediator of pathophysiological signals (oxidative distress) leading to growth arrest and regulated cell death[50]. One of the main intracellular sites of H_2O_2 production is the ER[51]. Along with the activation of peroxi-redoxins as possible intermediate sensors, the role of H_2O_2 in the development of the nervous system has been well-established[51-53]. Among targets of H_2O_2 redox signaling are transcription factors of the Wnt and the Shh pathways[54]. Moreover, H_2O_2 has been recently discovered as signaling molecule controlling axonal path finding in zebra fish[54] and neuronal growth cone collapse in vitro[55]. Hence, it is not surprising that a *TMX2* variant-mediated misbalance in oxidative eustress/distress could result in impaired neuronal development.

Under our experimental conditions, increased concentrations of H_2O_2 in the culture medium induced wild-type TMX2 dimerization. In the same maleimide alkylation assays, TMX2 redox state does not seem sensitive to ER stressors. These results reflect a physiological sensitivity of TMX2 to H_2O_2, possibly mimicking an adaptive response to oxidative eustress, regulating physiological steps in development[52; 54]. Wild-type TMX2 dimer was still slightly present under β-mercaptoethanol reducing conditions (Fig. S6), indicating that it is partially formed through inter-disulfide bonds. The occurrence of homo-dimerization of other members of the PDI superfamily has been described earlier (for PDI[56-58], PDIp[59], ERp29[60]) and is suggested as a general mechanism to regulate PDI function[13; 56]. Dimers can exhibit higher chaperone or unfolding activity as described for ERp29, PDIp, CNX and CRT dimerization[60]. Also, homo-dimerization of other TMX proteins has been postulated, e.g. a putative TMX1 homodimer was observed in immunoprecipitates with anti-CNX after ablation of the TRX domain active cysteines[61].

Our data suggest the formation of TMX2 homo-dimer/polymers, based on the evidence that observed TMX2 molecular masses on gradient gels show linearity with the predicted molecular mass by the Lambin method calculation and on the fact that the dimerization is not strictly dependent on disulfide bridge formation. Both under DTT pre-treatment in culture (of the TMX2 mutants) and by running a gel with β-mercaptoethanol, dimers are still present with an identical linear molecular mass. Since dimerization still occurs in the TRX domain mutant independently of an active cysteine and H_2O_2 treatment, the dimer does not represent a heterodimer of TMX2 with a substrate formed through mixed disulfides, similar to what is described for TMX1 homo-dimerization[61]. Although polymers were also observed after ablation of the TRX domain cysteine, they were barely present under reducing conditions. Hence, we cannot exclude interactions of TMX2 with other substrates of identical molecular mass, through TRX domain-independent interactions. For example, N-linked glycosylation has been shown to modulate the formation of PDI polymers and in TMX2 it could mediate interaction with heterologous peptides [56].

Similar to wild-type TMX2 under oxidative stress, we observed constitutive TMX2 homodi-/polymerization upon expression of the *TMX2* pathogenic variants (p.Arg53Cys and p.Arg231Trp), leading to mitochondrial dysfunction, reduced maximal respiration and increased glycolysis, as seen under ER stress conditions [7; 50; 62]. However, we did not detect activation of UPR in fibroblasts from affected individuals, both under native and under treatment with H_2O_2 (data not shown). This suggests that UPR is not the primary target of TMX2 function or that cultured fibroblasts are not the ideal test model.

Another fascinating aspect is TMX2 involvement in the pathogenesis of PMG. This malformation has long been considered as a defect of postmigratory cortical organization[63], with wide genetic heterogeneity, but also being a proven consequence of prenatal brain injury or disruptive events[64]. These aspects make genetic counseling of PMG most challenging. At brain imaging it may be difficult to distinguish PMG resulting from environmental factors (e.g. prenatal CMV infection) or from genetic defects. At MRI and pathological examination the main PMG characteristics are many small gyri with pebbled appearance, loss of normal cortical lamination, overfolding and fusion of the gyri, stippling of the white-grey matter border[65], sometimes giving the appearance of generally thickened cortex. The cobblestone malformation is characterized by pebbled cerebral surface, thick cortex and striation perpendicular to the cortical surface, which reflect tracks of neuroglial cells overmigrating above the glia limitans in the subarachnoid space, overmigration sometimes being massive and leading to thinning of the cortical plate [35; 66]. Cobblestone malformation is frequently associated with cerebellar and pons dysplasia and variable hydrocephalus, white matter and callosal dysgenesis. PMG and cobblestone malformation have been sporadically reported to coexist in the same genetic disorder[67; 68]. Pathology of the brain in two *TMX2* variant affected individuals shows a complete disorganization of the cortical layers (unlayered PMG) in both and in one of them (P10) diffusely overmigrating neurons, typical of cobblestone malformation, together with scattered white matter calcifications and pseudocysts, suggestive of a disruptive (CMV-like) event. Unlayered PMG is supposed to be caused by an early disruption of cortical development between 16-24 weeks gestation[69] and can also be observed in metabolic causes of PMG such as Zellweger disease (a peroxisomal biogenesis disorder, characterized by mislocalization of catalase), or lining non-genetic schizencephalic clefts[64; 70]. A mixture of disruptive and developmental migratory abnormalities has been reported for the brain disorder caused by the Zika virus (ZIKV) infection, where the effect on neuronal proliferation and migration is more prominent than in other more common congenital infections, i.e. CMV [71]. We demonstrate that TMX2-related PMG is a disorder of neuronal migration and cortical organization, without evidence of vascular or inflammatory disruption, in some cases with radiological aspect resembling an infectious i.e. non-genetic cause, in other cases microscopically showing the cobblestone malformation. These observations support the view that PMG and cobblestone are cortical malformations that can share a common pathogenesis and represent different severity of the spectrum[72; 73].

It is possible that some of the TMX2 related malformations are caused by lack of physiological response to regulators of neuronal development (hypothetically H_2O_2-mediated axonal pathfinding) and some are the effect of abnormal oxidoreductase-mediated protein folding and calcium homeostasis, with a secondary mitochondrial dysfunction. Although no UPR stimulation was found in TMX2 deficient cells, TMX2 also plays a role in regulation of UPR and apoptosis, both mechanisms essential for regulation of neuronal proliferation and cortical organization[74].

791 Our observation shows how in humans a genetic disorder of cellular redox adaptation mechanisms
792 can be the cause of neuronal proliferation and migration disorders, with characteristics of a
793 disruptive event. These studies also provide a mechanistic explanation for the fact that human brain
794 development is driven by steps strictly regulated in time and space, including individual response to
795 environmental stimuli, e.g. to redox signaling molecules and changes in cellular redox state. Protein
796 disulfide isomerase family members might prove to be major players in this process.
797

798 **SUPPLEMENTAL DATA**
799 Supplemental data include 8 figures and 5 tables.
800

801 **DECLARATION OF INTERESTS**
802 The authors declare no competing interests.
803

804 **ACKNOWLEGMENTS**

814 **FUNDING**

832

833 **WEB RESOURCES**
834 Allen Brain Atlas http://human.brain-map.org/

835   BWA http://bio-bwa.sourceforge.net/
836   DAVID https://david.ncifcrf.gov/
837   dbSNP https://www.ncbi.nlm.nih.gov/SNP/
838   ESP http://evs.gs.washington.edu/EVS/
839   ExAc database http://exac.broadinstitute.org
840   GeneMatcher http://www.genematcher.org
841   Genome Analysis Toolkit http://www.broadinstitute.org/gatk/
842   gnomAD database http://gnomad.broadinstitute.org
843   Ingenuity   https://www.qiagen.com/us/shop/analytics-software/biological-data-tools/ingenuity-
844   pathway-analysis/#orderinginformation
845   Mouse Genome Informatics http://www.informatics.jax.org/
846   OMIM https://www.omim.org/
847   R https://www.R-project.org/
848

849   **DATA AVAILABILITY AND ACCESSION NUMBERS**
850   WES data are deposited internally at the Erasmus MC and in each medical institute referring the
851   affected individuals, in respect to the privacy of the families. The mass spectrometry proteomics
852   data have been deposited in the ProteomeXchange Consortium[75] via the PRIDE[76] partner repository
853   with the dataset identifier PXD014064. The accession number for the RNAseq data reported in this
854   paper is Gene Expression Omnibus GSE133483.

855

856   **REFERENCES**
857   1. Gutiérrez, T., and Simmen, T. (2018). Endoplasmic reticulum chaperones tweak the mitochondrial
858   calcium rheostat to control metabolism and cell death. Cell Calcium 70, 64-75.

859   2. Pisoni, G.B., Ruddock, L.W., Bulleid, N., and Molinari, M. (2015). Division of labor among
860   oxidoreductases: TMX1 preferentially acts on transmembrane polypeptides. Molecular
861   Biology of the Cell 26, 3390-3400.

862   3. Galligan, J.J., and Petersen, D.R. (2012). The human protein disulfide isomerase gene family. Hum
863   Genomics 6, 6.

864   4. Ellgaard, L., and Ruddock, L.W. (2005). The human protein disulphide isomerase family: substrate
865   interactions and functional properties. EMBO Rep 6, 28-32.

866   5. Okumura, M., Kadokura, H., and Inaba, K. (2015). Structures and functions of protein disulfide
867   isomerase family members involved in proteostasis in the endoplasmic reticulum. Free
868   Radical Biology and Medicine 83, 314-322.

869   6. Sugiura, Y., Araki, K., Iemura, S., Natsume, T., Hoseki, J., and Nagata, K. (2010). Novel thioredoxin-
870   related transmembrane protein TMX4 has reductase activity. J Biol Chem 285, 7135-7142.

871   7. Raturi, A., Gutierrez, T., Ortiz-Sandoval, C., Ruangkittisakul, A., Herrera-Cruz, M.S., Rockley, J.P.,
872   Gesson, K., Ourdev, D., Lou, P.H., Lucchinetti, E., et al. (2016). TMX1 determines cancer cell
873   metabolism as a thiol-based modulator of ER-mitochondria Ca2+ flux. J Cell Biol 214, 433-
874   444.

875   8. Halperin, L., Jung, J., and Michalak, M. (2014). The many functions of the endoplasmic reticulum
876   chaperones and folding enzymes. IUBMB Life 66, 318-326.

877   9. Carreras-Sureda, A., Pihán, P., and Hetz, C. (2018). Calcium signaling at the endoplasmic reticulum:
878   fine-tuning stress responses. Cell Calcium 70, 24-31.

879   10. Lynes, E.M., Bui, M., Yap, M.C., Benson, M.D., Schneider, B., Ellgaard, L., Berthiaume, L.G., and
880   Simmen, T. (2012). Palmitoylated TMX and calnexin target to the mitochondria-associated
881   membrane. Embo j 31, 457-470.

882   11. Vance, J.E. (2014). MAM (mitochondria-associated membranes) in mammalian cells: lipids and
883   beyond. Biochim Biophys Acta 1841, 595-609.

884   12. Andreu, C.I., Woehlbier, U., Torres, M., and Hetz, C. (2012). Protein disulfide isomerases in
885   neurodegeneration: From disease mechanisms to biomedical applications. FEBS Letters 586,
886   2826-2834.

887   13. Parakh, S., and Atkin, J.D. (2015). Novel roles for protein disulphide isomerase in disease states: a
888   double edged sword? Frontiers in Cell and Developmental Biology 3, 30.

889   14. Perri, E.R., Thomas, C.J., Parakh, S., Spencer, D.M., and Atkin, J.D. (2015). The Unfolded Protein
890   Response and the Role of Protein Disulfide Isomerase in Neurodegeneration. Front Cell Dev
891   Biol 3, 80.

892   15. Rauch, F., Fahiminiya, S., Majewski, J., Carrot-Zhang, J., Boudko, S., Glorieux, F., Mort, J.S.,
893   Bachinger, H.P., and Moffatt, P. (2015). Cole-Carpenter syndrome is caused by a
894   heterozygous missense mutation in P4HB. Am J Hum Genet 96, 425-431.

895   16. Abdel-Salam, G., Thoenes, M., Afifi, H.H., Körber, F., Swan, D., and Bolz, H.J. (2014). The
896   supposed tumor suppressor gene WWOX is mutated in an early lethal microcephaly
897   syndrome with epilepsy, growth retardation and retinal degeneration. Orphanet journal of
898   rare diseases 9, 12-12.

899   17. Zolotushko, J., Flusser, H., Markus, B., Shelef, I., Langer, Y., Heverin, M., Björkhem, I., Sivan, S.,
900   and Birk, O.S. (2011). The desmosterolosis phenotype: spasticity, microcephaly and
901   micrognathia with agenesis of corpus callosum and loss of white matter. European journal of
902   human genetics : EJHG 19, 942-946.

903   18. Hoefs, S.J., Skjeldal, O.H., Rodenburg, R.J., Nedregaard, B., van Kaauwen, E.P., Spiekerkotter, U.,
904   von Kleist-Retzow, J.C., Smeitink, J.A., Nijtmans, L.G., and van den Heuvel, L.P. (2010). Novel
905   mutations in the NDUFS1 gene cause low residual activities in human complex I deficiencies.
906   Mol Genet Metab 100, 251-256.

907   19. Wortmann, S.B., Vaz, F.M., Gardeitchik, T., Vissers, L.E.L.M., Renkema, G.H., Schuurs-
908   Hoeijmakers, J.H.M., Kulik, W., Lammens, M., Christin, C., Kluijtmans, L.A.J., et al. (2012).
909   Mutations in the phospholipid remodeling gene SERAC1 impair mitochondrial function and
910   intracellular cholesterol trafficking and cause dystonia and deafness. Nature Genetics 44,
911   797.

912   20. Larrea, D., Pera, M., Gonnelli, A., Quintana–Cabrera, R., Akman, H.O., Guardia-Laguarta, C.,
913   Velasco, K.R., Area-Gomez, E., Dal Bello, F., De Stefani, D., et al. (2019). MFN2 mutations in
914   Charcot–Marie–Tooth disease alter mitochondria-associated ER membrane function but do
915   not impair bioenergetics. Human Molecular Genetics 28, 1782-1800.

916 21. Meng, X., Zhang, C., Chen, J., Peng, S., Cao, Y., Ying, K., Xie, Y., and Mao, Y. (2003). Cloning and
917   identification of a novel cDNA coding thioredoxin-related transmembrane protein 2.
918   Biochem Genet 41, 99-106.

919 22. Chao, R., Nevin, L., Agarwal, P., Riemer, J., Bai, X., Delaney, A., Akana, M., JimenezLopez, N.,
920   Bardakjian, T., Schneider, A., et al. (2010). A male with unilateral microphthalmia reveals a
921   role for TMX3 in eye development. PloS one 5, e10565-e10565.

922 23. Sobreira, N., Schiettecatte, F., Valle, D., and Hamosh, A. (2015). GeneMatcher: a matching tool
923   for connecting investigators with an interest in the same gene. Hum Mutat 36, 928-930.

924 24. Zillhardt, J.L., Poirier, K., Broix, L., Lebrun, N., Elmorjani, A., Martinovic, J., Saillour, Y., Muraca, G.,
925   Nectoux, J., Bessieres, B., et al. (2016). Mosaic parental germline mutations causing
926   recurrent forms of malformations of cortical development. Eur J Hum Genet 24, 611-614.

927 25. Judas, M., Simic, G., Petanjek, Z., Jovanov-Milosevic, N., Pletikos, M., Vasung, L., Vuksic, M., and
928   Kostovic, I. (2011). The Zagreb Collection of human brains: a unique, versatile, but
929   underexploited resource for the neuroscience community. Ann N Y Acad Sci 1225 Suppl 1,
930   E105-130.

931 26. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and
932   Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21.

933 27. Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general purpose program for
934   assigning sequence reads to genomic features. Bioinformatics 30, 923-930.

935 28. Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor package for
936   differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140.

937 29. Huang da, W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and integrative analysis of
938   large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44-57.

939 30. Huang da, W., Sherman, B.T., and Lempicki, R.A. (2009). Bioinformatics enrichment tools: paths
940   toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37, 1-13.

941 31. Oegema, R., Baillat, D., Schot, R., van Unen, L.M., Brooks, A., Kia, S.K., Hoogeboom, A.J.M., Xia, Z.,
942   Li, W., Cesaroni, M., et al. (2017). Human mutations in integrator complex subunits link
943   transcriptome integrity to brain development. PLoS Genet 13, e1006809.

944 32. Vandervore, L.V., Schot, R., Kasteleijn, E., Oegema, R., Stouffs, K., Gheldof, A., Grochowska,
945   M.M., van der Sterre, M.L.T., van Unen, L.M.A., Wilke, M., et al. (2019). Heterogeneous
946   clinical phenotypes and cerebral malformations reflected by rotatin cellular dynamics. Brain
947   : a journal of neurology 142, 867-884.

948 33. Milanese, C., Payán-Gómez, C., Galvani, M., Molano González, N., Tresini, M., Nait Abdellah, S.,
949   van Roon-Mom, W.M.C., Figini, S., Marinus, J., van Hilten, J.J., et al. (2019). Peripheral
950   mitochondrial function correlates with clinical severity in idiopathic Parkinson's disease.
951   Movement Disorders.

952 34. Matsuo, Y., and Hirota, K. (2017). Transmembrane thioredoxin-related protein TMX1 is reversibly
953   oxidized in response to protein accumulation in the endoplasmic reticulum. FEBS Open Bio
954   7, 1768-1777.

955 35. Devisme, L., Bouchet, C., Gonzalès, M., Alanio, E., Bazin, A., Bessières, B., Bigi, N., Blanchet, P.,
956   Bonneau, D., Bonnières, M., et al. (2012). Cobblestone lissencephaly: neuropathological
957   subtypes and correlations with genes of dystroglycanopathies. Brain 135, 469-482.

958 36. Zhang, Z., Xin, D., Wang, P., Zhou, L., Hu, L., Kong, X., and Hurst, L.D. (2009). Noisy splicing, more
959   than expression regulation, explains why some exons are subject to nonsense-mediated
960   mRNA decay. BMC biology 7, 23-23.

961 37. Zou, W., Bai, Y., Wang, X., Cheng, K., Sun, H., Zhang, G., and Yang, Z. (2017). PERK-
962   Phosphorylated eIF2alpha Pathway Suppresses Tumor Metastasis Through Downregulating
963   Expression of Programmed Death Ligand 1 and CXCL5 in Triple-Negative Breast Cancer.
964   Cancer Biother Radiopharm 32, 282-287.

965 38. Gade, P., Ramachandran, G., Maachani, U.B., Rizzo, M.A., Okada, T., Prywes, R., Cross, A.S., Mori,
966   K., and Kalvakolanu, D.V. (2012). An IFN-gamma-stimulated ATF6-C/EBP-beta-signaling
967   pathway critical for the expression of Death Associated Protein Kinase 1 and induction of
968   autophagy. Proc Natl Acad Sci U S A 109, 10316-10321.

969 39. Nita, I., Hostettler, K., Tamo, L., Medova, M., Bombaci, G., Zhong, J., Allam, R., Zimmer, Y., Roth,
970   M., Geiser, T., et al. (2017). Hepatocyte growth factor secreted by bone marrow stem cell
971   reduce ER stress and improves repair in alveolar epithelial II cells. Sci Rep 7, 41901.

972 40. Wolters, P.J., Collard, H.R., and Jones, K.D. (2014). Pathogenesis of idiopathic pulmonary fibrosis.
973   Annual review of pathology 9, 157-179.

974 41. Wu, R., Zhang, Q.-H., Lu, Y.-J., Ren, K., and Yi, G.-H. (2015). Involvement of the IRE1α-XBP1
975   pathway and XBP1s-dependent transcriptional reprogramming in metabolic diseases. DNA
976   and cell biology 34, 6-18.

977 42. Jessop, C.E., Watkins, R.H., Simmons, J.J., Tasab, M., and Bulleid, N.J. (2009). Protein disulphide
978   isomerase family members show distinct substrate specificity: P5 is targeted to BiP client
979   proteins. J Cell Sci 122, 4287-4295.

980 43. Horna-Terrón, E., Pradilla-Dieste, A., Sánchez-de-Diego, C., and Osada, J. (2014). TXNDC5, a newly
981   discovered disulfide isomerase with a key role in cell physiology and pathology. International
982   journal of molecular sciences 15, 23501-23518.

983 44. Lakkaraju, A.K., Abrami, L., Lemmin, T., Blaskovic, S., Kunz, B., Kihara, A., Dal Peraro, M., and van
984   der Goot, F.G. (2012). Palmitoylated calnexin is a key component of the ribosome-translocon
985   complex. The EMBO journal 31, 1823-1835.

986 45. Harbauer, A.B., Zahedi, R.P., Sickmann, A., Pfanner, N., and Meisinger, C. (2014). The protein
987   import machinery of mitochondria-a regulatory hub in metabolism, stress, and disease. Cell
988   Metab 19, 357-372.

989 46. Liu, J., Wang, Y., Song, L., Zeng, L., Yi, W., Liu, T., Chen, H., Wang, M., Ju, Z., and Cong, Y.-S.
990   (2017). A critical role of DDRGK1 in endoplasmic reticulum homoeostasis via regulation of
991   IRE1α stability. Nature Communications 8, 14186.

992 47. Lambin, P. (1978). Reliability of molecular weight determination of proteins by polyacrylamide
993   gradient gel electrophoresis in the presence of sodium dodecyl sulfate. Analytical
994   Biochemistry 85, 114-125.

995 48. Gilady, S.Y., Bui, M., Lynes, E.M., Benson, M.D., Watts, R., Vance, J.E., and Simmen, T. (2010).
996   Ero1alpha requires oxidizing and normoxic conditions to localize to the mitochondria-
997   associated membrane (MAM). Cell Stress Chaperones 15, 619-629.

998 49. Yoshihara, E., Chen, Z., Matsuo, Y., Masutani, H., and Yodoi, J. (2010). Thiol redox transitions by
999   thioredoxin and thioredoxin-binding protein-2 in cell signaling. Methods Enzymol 474, 67-82.

1000 50. Sies, H. (2017). Hydrogen peroxide as a central redox signaling molecule in physiological
1001   oxidative stress: Oxidative eustress. Redox Biol 11, 613-619.

1002 51. Winterbourn, C.C. (2017). Biological Production, Detection, and Fate of Hydrogen Peroxide.
1003   Antioxidants & Redox Signaling 29, 541-551.

1004 52. Olguín-Albuerne, M., and Morán, J. (2017). Redox Signaling Mechanisms in Nervous System
1005   Development. Antioxidants & Redox Signaling 28, 1603-1625.

1006 53. Oswald, M.C.W., Garnham, N., Sweeney, S.T., and Landgraf, M. (2018). Regulation of neuronal
1007   development and function by ROS. FEBS letters 592, 679-691.

1008 54. Gauron, C., Meda, F., Dupont, E., Albadri, S., Quenech'Du, N., Ipendey, E., Volovitch, M., Del
1009   Bene, F., Joliot, A., Rampon, C., et al. (2016). Hydrogen peroxide (H2O2) controls axon
1010   pathfinding during zebrafish development. Developmental biology 414, 133-141.

1011 55. Morinaka, A., Yamada, M., Itofusa, R., Funato, Y., Yoshimura, Y., Nakamura, F., Yoshimura, T.,
1012   Kaibuchi, K., Goshima, Y., Hoshino, M., et al. (2011). Thioredoxin mediates oxidation-
1013   dependent phosphorylation of CRMP2 and growth cone collapse. Sci Signal 4, ra26.

1014 56. Walker, A.K., Soo, K.Y., Levina, V., Talbo, G.H., and Atkin, J.D. (2013). N-linked glycosylation
1015   modulates dimerization of protein disulfide isomerase family A member 2 (PDIA2). Febs j
1016   280, 233-243.

1017 57. Solovyov, A., and Gilbert, H.F. (2004). Zinc-dependent dimerization of the folding catalyst,
1018   protein disulfide isomerase. Protein science : a publication of the Protein Society 13, 1902-
1019   1907.

1020 58. Bastos-Aristizabal, S., Kozlov, G., and Gehring, K. (2014). Structural insight into the dimerization
1021   of human protein disulfide isomerase. Protein science : a publication of the Protein Society
1022   23, 618-626.

1023 59. Fu, X.M., and Zhu, B.T. (2009). Human pancreas-specific protein disulfide isomerase homolog
1024   (PDIp) is an intracellular estrogen-binding protein that modulates estrogen levels and actions
1025   in target cells. J Steroid Biochem Mol Biol 115, 20-29.

1026 60. Rainey-Barger, E.K., Mkrtchian, S., and Tsai, B. (2007). Dimerization of ERp29, a PDI-like protein,
1027   is essential for its diverse functions. Mol Biol Cell 18, 1253-1260.

1028 61. Matsuo, Y., Masutani, H., Son, A., Kizaka-Kondoh, S., and Yodoi, J. (2009). Physical and functional
1029   interaction of transmembrane thioredoxin-related protein with major histocompatibility
1030   complex class I heavy chain: redox-based protein quality control and its potential relevance
1031   to immune responses. Mol Biol Cell 20, 4552-4562.

1032 62. Hetz, C. (2012). The unfolded protein response: controlling cell fate decisions under ER stress and
1033   beyond. Nat Rev Mol Cell Biol 13, 89-102.

1034 63. Barkovich, A.J., Guerrini, R., Kuzniecky, R.I., Jackson, G.D., and Dobyns, W.B. (2012). A
1035   developmental and genetic classification for malformations of cortical development: update
1036   2012. Brain 135, 1348-1369.

1037 64. Stutterd, C.A., and Leventer, R.J. (2014). Polymicrogyria: a common and heterogeneous
1038   malformation of cortical development. Am J Med Genet C Semin Med Genet 166c, 227-239.

1039 65. Leventer, R.J., Jansen, A., Pilz, D.T., Stoodley, N., Marini, C., Dubeau, F., Malone, J., Mitchell, L.A.,
1040   Mandelstam, S., Scheffer, I.E., et al. (2010). Clinical and imaging heterogeneity of
1041   polymicrogyria: a study of 328 patients. Brain 133, 1415-1427.

1042 66. Brun, B.N., Mockler, S.R.H., Laubscher, K.M., Stephan, C.M., Wallace, A.M., Collison, J.A.,
1043   Zimmerman, M.B., Dobyns, W.B., and Mathews, K.D. (2017). Comparison of brain MRI
1044   findings with language and motor function in the dystroglycanopathies. Neurology 88, 623-
1045   629.

1046 67. Bahi-Buisson, N., Poirier, K., Boddaert, N., Fallet-Bianco, C., Specchio, N., Bertini, E., Caglayan, O.,
1047   Lascelles, K., Elie, C., Rambaud, J., et al. (2010). GPR56-related bilateral frontoparietal
1048   polymicrogyria: further evidence for an overlap with the cobblestone complex. Brain 133,
1049   3194-3209.

1050 68. Jaglin, X.H., Poirier, K., Saillour, Y., Buhler, E., Tian, G., Bahi-Buisson, N., Fallet-Bianco, C., Phan-
1051   Dinh-Tuy, F., Kong, X.P., Bomont, P., et al. (2009). Mutations in the beta-tubulin gene
1052   TUBB2B result in asymmetrical polymicrogyria. Nat Genet 41, 746-752.

1053 69. Barth, P.G. (1987). Disorders of Neuronal Migration. Canadian Journal of Neurological Sciences /
1054   Journal Canadien des Sciences Neurologiques 14, 1-16.

1055 70. Liu, H.M., Bangaru, B.S., Kidd, J., and Boggs, J. (1976). Neuropathological considerations in
1056   cerebro-hepato-renal syndrome (Zellweger's syndrome). Acta Neuropathol 34, 115-123.

1057 71. Melo, A.S.d.O., Aguiar, R.S., Amorim, M.M.R., Arruda, M.B., Melo, F.d.O., Ribeiro, S.T.C., Batista,
1058   A.G.M., Ferreira, T., dos Santos, M.P., Sampaio, V.V., et al. (2016). Congenital Zika Virus
1059   Infection: Beyond Neonatal MicrocephalyCongenital Zika Virus InfectionCongenital Zika Virus
1060   Infection. JAMA Neurology 73, 1407-1416.

1061 72. Jansen, A.C., Robitaille, Y., Honavar, M., Mullatti, N., Leventer, R.J., Andermann, E., Andermann,
1062   F., and Squier, W. (2016). The histopathology of polymicrogyria: a series of 71 brain autopsy
1063   studies. Developmental Medicine & Child Neurology 58, 39-48.

1064 73. Squier, W., and Jansen, A. (2014). Polymicrogyria: pathology, fetal origins and mechanisms. Acta
1065   Neuropathol Commun 2, 80.

1066 74. Laguesse, S., Creppe, C., Nedialkova, D.D., Prevot, P.P., Borgs, L., Huysseune, S., Franco, B.,
1067   Duysens, G., Krusy, N., Lee, G., et al. (2015). A Dynamic Unfolded Protein Response
1068   Contributes to the Control of Cortical Neurogenesis. Dev Cell 35, 553-567.

1069 75. Deutsch, E.W., Csordas, A., Sun, Z., Jarnuczak, A., Perez-Riverol, Y., Ternent, T., Campbell, D.S.,
1070   Bernal-Llinares, M., Okuda, S., Kawano, S., et al. (2017). The ProteomeXchange consortium in
1071   2017: supporting the cultural change in proteomics public data deposition. Nucleic Acids Res
1072   45, D1100-d1106.

1073 76. Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S., Kundu, D.J., Inuganti,
1074   A., Griss, J., Mayer, G., Eisenacher, M., et al. (2019). The PRIDE database and related tools
1075   and resources in 2019: improving support for quantification data. Nucleic acids research 47,
1076   D442-D450.

1077

1078 **FIGURE TITLES AND LEGENDS**

1079 **Figure 1. Features and brain MRI of individuals with *TMX2* variants.** P indicates the code of the
1080 probands as used in Table 1 and S4. P1 (**A-E**): affected member of family 1. **A:** The photograph shows
1081 mild microcephaly and no overt dysmorphic features. The MRI scan at birth shows T2 weighted
1082 images, of (**B**) parasagittal plane, (**C**) axial at the level of basal ganglia, (**D**) axial at the level of parietal
1083 areas and € axial at the level of pons and cerebellum. Both the parasagittal and the two axial
1084 cerebral sections show diffuse polymicrogyria of the cortex, normal myelination, hypointensity of
1085 the thalami (left axial) and normal cerebellum. P2 (**F-H**): MRI of the affected individual from family 2
1086 at 19 months of age. (**F**) axial FLAIR -, (**G**) coronal T2 -, (**H**) coronal inversion recovery- weighted
1087 images all showing bilateral diffuse thickened cortex extending through frontal, parietal and occipital
1088 areas, resembling polymicrogyria, with sparing of the cerebellum. The lateral ventricles are enlarged
1089 and asymmetric; the periventricular white matter volume is strongly reduced. P3 (**I**): axial T2
1090 weighted image of the affected child of family 3 at birth, showing diffuse bilateral polymicrogyria of
1091 the cortex, mild dilatation of the posterior horns of the lateral ventricles and delayed myelination.
1092 P4 (**J-L**) and P5 (**M-O**): affected siblings of family 4, at the age of 12 (P4) and 23 years (P5),
1093 respectively (**J and M**) sagittal T1-, (**K and N**) axial T2- weighted images at the level of basal ganglia
1094 and (**L and O**) the cerebellum, showing thin corpus callosum, loss of periventricular white matter and
1095 volume of thalami, deep cerebral sulci and mild cerebellar atrophy. No cortical malformation is
1096 present. P6 (**P-S**) is the index of family 5. (**P**) Axial T2 and (**Q**) parasagittal T1 images showing
1097 abnormally thick cortex, atrophic thalami, in (**Q**) the frontal cortex looks pachygyric. (**R**) Axial T2
1098 FLAIR and (**S**) axial T1 weighted images showing diffusely thickened cortex, most prominent in
1099 parietal areas and moderately enlarged lateral ventricles. P9 (**T-V**): affected proband of family 6, at
1100 the age of 11 months. Axial T2 weighted images (**T-U**) showing brain atrophic changes with bilateral
1101 pallidus (red arrow) and posterior limb of the internal capsule (red arrowhead) T2 high signal
1102 intensity, as well as significant delayed myelination. Globi pallidi are severely atrophic. (**V**): Both
1103 globi pallidi, posterior limb of the internal capsules, optic radiations (black arrowhead) and
1104 brainstem tract (not shown) abnormalities are also noted on DWI and confirmed by ADC map (not
1105 shown) indicating restricted diffusion. P10 (**W-Y**): MRI at birth of the proband from family 7. (**W**)
1106 midsagittal, (**X-Y**) axial T2 weighted images. (**W**) mild hypoplasia of the pons, thin corpus callosum.
1107 (**X**) hypoplastic cerebral peduncles, bilateral abnormal cortex with polymicrogyric appearance. (**Y**)
1108 diffuse bilateral polymicrogyria, enlarged lateral ventricles with pseudocyst in the left occipital horn
1109 (black arrowhead), and white matter loss, the combination including the pseudocyst being typically
1110 seen in CMV infections.

1111 **Figure 2. Brain pathology of individuals with *TMX2* variants.** A-C, E-G: affected individuals; D and H:
1112 age matched controls. Upper panel: macroscopic brain appearance of P1 (**A-B**) and P10 (**C**). Sagittal
1113 view (**A**) and coronal section (**B**) show diffuse bilateral excessive amount of small gyri
1114 (polymicrogyria) of the cerebral cortex (most affected areas indicated by white arrows), compared to
1115 control brain (**D**). (**C**) coronal section through the posterior parts of the brain shows asymmetric

1116   hemispheres and bilateral polymicrogyria, especially in the occipital lobes (white arrow). The image
1117   of the normal neonatal age-matched brain (40GW), shows normal size and number of the gyri and
1118   sulci (lateral view of the right hemisphere) (**D**). Lower panel: Histological sections of individuals P1
1119   (**E-F**), P10 (**G**) and age matched control brain cortex (**H**) show absence of normal cortical layers in
1120   affected individuals, with bands of neurons laying perpendicular to the cortical surface in E, F and G.
1121   Undulating bands of neurons (arrow heads), entrapped pial vessels mimicking fusion of the cortical
1122   layer (arrow), and thickened leptomeninges are compatible with (unlayered) polymicrogyria (**E:** H&E,
1123   10x, **F:** H&E, 5x, **G:** Lugol-PAS stain, 3x). Control histological section of the frontal dorsolateral
1124   telencephalic gyrus of the neonatal age-matched brain (**H**: H&E 5x), showed the regular organization
1125   of the six-layered neonatal neocortex, parallel to the pia surface.

1126

1127   **Figure 3. Genomic and transcriptomic analysis of *TMX2* variants**. **A.** Schematic overview of *TMX2,*
1128   protein domains and the discovered variants in affected individuals (GSDS 2.0) **B.** Levels of expressed
1129   *TMX2* messenger RNA in individuals P1, P2 and P3. Ct values were normalized with two
1130   housekeeping genes *CLK2* and *RNF111*(ΔΔ CT relative to control (n=2). Data are represented as the
1131   mean ± SEM. Statistical two-tailed unpaired t-tests were performed with confidence interval 95%. **C.**
1132   Allele specific qPCR of individual P1. Ct values were normalized with two housekeeping genes CLK2
1133   and RNF111 (ΔΔ CT relative to control (n=4). **D.** Aberrant splicing of the P2 and control *TMX2* alleles.
1134   Graphic illustration (adapted from IGV Sashimi plot) of the percentage of *TMX2* transcripts in
1135   RNAseq data of total RNA of individual P2 and 1 control individual. Percentages are calculated for
1136   each transcript compared to the total *TMX2* (wild-type and alternative) transcript reads (GRCh38),
1137   and **E.** Aberrant splicing of the P2 and control *TMX2* alleles. Aligned uniquely mapped reads in the
1138   exon 5-7 region of *TMX2* were quantified (reads per million) using IGV 2.3.26. Three distinct
1139   alternative species of *TMX2* transcript were identified, consistent with intron 6 retention, exon 6
1140   skipping and exon 6 internal splice site usages, the latter two only from the P2 allele. Total uniquely
1141   mapped reads for control and individual P2 were 64 745 034 and 54 200 090 respectively.
1142
1143   **Figure 4. Gene ontology (GO) analysis of differentially expressed genes in *TMX2* variants**. **A.** DAVID
1144   Functional Annotation Clustering (FAC) analysis of the top 1000 differentially expressed genes (DEGs)
1145   obtained by comparison of two *TMX2* affected individuals vs. three age and gender matched control
1146   RNA samples (p-value <0.05). **B.** upper panel: LogFC of all differentially expressed disulfide bond
1147   associated genes in *TMX2* affected individuals with an FDR<0.05, lower panel: -Log(FDR) of these
1148   genes (-log(FDR)<1.3). **C.** Ingenuity Pathway analysis (IPA) was performed to determine activated
1149   and inhibited biological functions downstream of the differentially expressed genes in *TMX2* affected
1150   individuals. Stringency was determined with 90% confidence interval by only considering activation
1151   Z-scores higher than 1.65 (activation) or lower than -1.65 (inhibition). Individual p-values of each
1152   function are mentioned within the bars and were always lower than 10^{-6}. **Abbreviations:** GO, Gene
1153   ontology; UP, UniProtKB; FDR, False discovery rate; FC, Fold Change; KEGG, Kyoto Encyclopedia of
1154   Genes and Genomes.

1155   **Figure 5. Proteomics analysis of exogenous TMX2 interacting proteins**. **A.** HEK293T cells were
1156   transfected with Myc-tagged TMX2 or negative control β-lactamase for 24 hours, followed by IP with
1157   αMyc antibody and LC-MS/MS on bead pellets. Detected proteins interacting with TMX2-Myc but
1158   not with Lac-Myc were filtered based on average Mascot score in n=4 experiments (significant if
1159   higher than 40). Cytoscape String App visualized all 71 proteins reproducibly and selectively

interacting with TMX2 according to pathway involvement (dark blue=Protein folding, light blue= Calcium Homeostasis, Red= ER associated degradation (ERAD) and Unfolded Protein Response (UPR), Green= Mitochondrial signaling, Pink= Mitosis, Orange= Translation, Yellow= Nucleus Transport, Black=Golgi transport, Grey=unassigned). Known PDI interactors Calnexin and SERCA2 were found in the top 10 highest interactions, and are circled in red. **B.** HEK293T cells were transfected with Myc-tagged TMX2 or negative control β-lactamase for 24 hours, followed by reciprocal immunoprecipitation of SERCA2 (Mouse monoclonal anti-SERCA2 ATPase ab2861) and Calnexin (Monoclonal Rabbit anti-human CNX C5C9), SDS PAGE and detection of TMX2 with αMyc antibody. IP input is shown after reducing western blot.

Figure 6. Bioenergetics profiles of skin fibroblasts from affected individuals with *TMX2* variants. A, B. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) bioenergetics profiles of fibroblasts derived from healthy controls (n=4) and affected individuals (P1, P2, P3). Fibroblasts were challenged with sequential administration of oligomycin to inhibit ATP synthase, FCCP to elicit maximal respiration, rotenone to inhibit complex I, and antimycin to inhibit complex III and fully block respiration. The parameters analyzed in the profiles were: basal respiration, respiration dedicated to ATP production, (measured as difference between basal respiration and the respiration after oligomycin injection), mitochondrial reserve capacity (as difference between maximum reserve capacity and basal respiration), and rotenone sensitive respiration (which accounts for the respiration dependent on complex I), basal glycolysis and oligomycin stimulated glycolysis. **C, D.** Fibroblasts derived from affected individuals show significant reduction in mitochondrial reserve capacity and in the complex I activity (**C**) while showing a significant potentiation of glycolysis in basal condition and upon stimulation with oligomycin (**D**). **E.** The analysis of mitochondrial respiration in galactose medium (where glycolysis is not permitted) highlights the inability of the *TMX2* variant fibroblasts to potentiate basal mitochondrial respiration and mitochondrial complex I activity. (*$p < 0.05$; **$p < 0.01$; ****$p < 0.0001$; one-way ANOVA (C, D) and two-way ANOVA (E) followed by Dunnett's multiple-comparison post doc test). Graphs represent mean ± SEM.

Figure 7. Redox state assays of wild-type and variant TMX2. **A-B**. Non-reducing western blot of exogenous wild-type TMX2 versus endogenous control PDI (PDIA1) in HEK293T cells, showing that TMX2 occurs in an oxidized and reduced monomeric form, while during H_2O_2 treatment a dimer is formed (OX dimer). A) left panel shows the blot after incubation with anti-wild-type TMX2 antibodies; middle panel: incubation with anti-Myc antibodies; right panel: anti-PDI control protein antibodies. B) Control experiment after expression of exogenous control β-lactamase (Lac-Myc); immunoblotting performed with the same antibodies as in A. Native: untreated cells; BFA: cells treated with ER stress inducer Brefeldin A; DTT: cells treated with reducing agent DL-Dithiothreitol; H2O2: cells treated with hydrogen peroxide.
C. Non-reducing western blot with similar experimental setup as in A and B. but here also after addition of ER stress inducers Tunicamycin (TM) and Thapsigargin (TG). Redox states of TRX domain p.Cys170Gly variant (lanes 7-12) and affected individual p.Arg53Cys variant (lanes 13-18) and p.Arg231Trp variant (lanes 19-24) were determined simultaneously. Detection was performed with anti-Myc antibody. **D-E.** Semi quantitative densitometry calculations of TMX2 dimer/monomer ratios in native, ER stress, oxidative and reductive environment for wild-type TMX2, n=4 western blots from biological replicates (**D.**) and comparing wild-type TMX2 to p.Cys170Gly, p.Arg53Cys and p.Arg231Trp variants. Data are represented as the mean ± SEM. Statistical two-tailed unpaired t-

1205   tests were performed with confidence interval 95% in Graphpad Prism 8 (*$p < 0.05$; **$p < 0.01$;

1206   ***$p<0.001$, ****$p < 0.0001$).

Table 1 Summary of *TMX2* variants and phenotypes.

Affected individuals	Family 1- P1	Family 2- P2	Family 3-P3	Family 4- P4	Family 4- P5	Family 5-P6 [24]	Family 5-P7 [24]	Family 6- P8	Family 6- P9	Family 7- P10	Family 8- P11	Family 8- P12	Family 9- P13	Family 10- P14
Ancestry	Dutch	Portuguese	White British	Puerto Rican	Puerto Rican	Spanish	Spanish	Arab	Arab	Dutch	Iraqi	Iraqi	Pakistani	Mexican
cDNA alteration	c.164A>C; c.391dup	c.614G>A Homozygote	c.157C>T; c.757C>T	c.166G>C Homozygote	c.166G>C Homozygote	c.326A>G; c.691C>T	c.326A>G; c.691C>T	Not tested	c.532G>A Homozygote	c.164A>C;c.609 _614+15del	c.184G>C Homozygote	c.184G>C Homozygote	c.178G>A Homozygote	c.349A>G; c.691C>T
Protein alteration	p.Asp55Ala;p.L eu131Profs*6	p.Arg205Gln	p.Arg53Cys;p.A rg253*	p.Gly56Arg	p.Gly56Arg	p.Asp109Gly;p. Arg231Trp	p.Asp109Gly;p. Arg231Trp	Not tested	p.Ala178Thr	p.Asp55Ala;p.S er203_Thr204d el	p.Asp62His	p.Asp62His	p.Asp60Asn	p.Ile117Val;p.A rg231Trp
Gender	Male	Male	Female	Male	Female	Female	Male	Female	Female	Male	Male	Male	Female	Female
Head size (OFC)	Primary microcephaly (- 3 SD at birth)	Microcephaly (n.a. at birth; - 4.5 SD current)	Primary microcephaly (- 2.5 SD at birth, - 6.7 SD current)	Borderline microcephaly (n.a. at birth; - 2 SD current)	Microcephaly (n.a. at birth; - 3 SD current)	Microcephaly (- 2 SD at birth; - 4 SD current)	Microcephaly (n.a. at birth; - 3 SD current)	Undefined (0 SD at birth, later n.a.)	Microcephaly (0 SD at birth; - 5.5 SD current)	Primary microcephaly (- 2.5 SD at birth)	Microcephaly (n.a. at birth; - 4.5 SD current)	Primary microcephaly (- 2,5 SD at birth; - 3.5 SD current)	Normal (n.a. at birth; - 0.5 SD current)	Normal (n.a. at birth; - 0.8 SD current)
Neurological impairment	No developmental milestones[a]	CP, no speech or ambulation	CP, no speech or ambulation	CP, no speech or ambulation	CP, no speech or ambulation	CP, no speech or ambulation	CP, no speech or ambulation	CP, no speech or ambulation	CP, no speech or ambulation	No developmental milestones[a]	No ambulation, few words	No speech or ambulation	Able to walk with support, few words	IQ 62; language disorder; hyperactive behavior, able to walk
Survival/ age at last examination	Deceased at week 2	7 yr.	9 yr.	28 yr.	25 yr.	13 yr.	11 yr.	Deceased at 6 yr.	1.5 yr.	Deceased at 1 week	10 yr.	5 yr.	4.8 yr.	11.5 yr.
Epilepsy	Generalized, apnea, status epilepticus	Generalized, absence, spasms	Generalized seizures	Focal seizures	Myoclonic-absence, GTC	No seizures	GTC	GTC	Focal seizures	Apnea, diaphragmatic myoclonia	Generalized tonic, myoclonic seizures	GTC	Myoclonic status epilepticus	No seizures
MRI	Polymicrogyria	Polymicrogyria	Polymicrogyria	Progressive brain atrophy	Progressive brain atrophy	Pachygyria	Pachygyria	Severe brain atrophy	Sever brain atrophy	Polymicrogyria	n.a.	Polymicrogyria	Hemihypertrop hy and frontal dysgyria	Normal
Brain autopsy	Unlayered polymicrogyria and complete cortical disorganization	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Diffuse polymicrogyria and cobblestone-like malformation	n.a.	n.a.	n.a.	n.a.

[a] **These individuals passed away soon after birth. Microcephaly is defined as an OFC $\leq$-2.5SD. Abbreviations: CP, signs of cerebral palsy; n.a., not assessed or not available; OFC, Occipitofrontal circumference; yr., year; SD, standard deviations; GTC, Generalized tonic clonic seizures**

Figure 1   Click here to access/download;Figure;Figure-1_resized2.tif ⬇

Individual P1

Individual P2   Individual P3

Individual P4   Individual P5

Individual P5   Individual P6

Individual P6   Individual P8

Individual P9   Individual P10

Figure 2   Click here to access/download;Figure;figure2_DS.tif ⬇

Individual P1

Individual P10   Age-matched control

Individual P1

Individual P10   Age-matched control

Figure 3   Click here to access/download;Figure;figure3_revision4.tif ⬇

A

CYTOSOL   MAM   ER LUMEN

TMX2

p.Arg53Cys   p.Gly56Arg   p.Asp109Gly   p.Ser203_Thr204del

5'   3'

p.Asp55Ala   p.Asp62His   p.Ile117Val   p.Leu131Profs*6   p.Ala178Thr   p.Arg205Gln   p.Arg231Trp   p.Arg253*

p.Asp60Asn

Legend:

Exon   Intron

100 bp

NH2 terminal signal sequence   Transmembrane domain   Thioredoxin domain (SNDC)   Possible Myb DNA binding domain   ER retention domain (KKDK)

B *TMX2* mRNA expression

Fold Change

p = 0.0238

p = 0.0001

1.5

1.0

0.5

0.0

Control (n=13)   P1: c.164A>C;c.391dup   P2: c.614G>A   P3: c.157C>T;c.757C>T

C Allele specific *TMX2* mRNA

Fold Change

1.5

1.0

0.5

0.0

P<0.0001   P<0.0001

Control (N=5)   Individual P1

TMX2 c.391dup   TMX2 c.164A>C

E Alternative Splicing

Intron 6 retention
Exon 6 skipping (-66 nt)
Exon 6 internal (-11 nt)
Regular

Intron 6 retention
Exon 6 skipping (-66 nt)   0
Exon 6 internal (-11 nt)   0
Regular

0.0   1.0   2.0   3.0   4.0   5.0   6.0

Control   Reads per million mapped

Individual P2

D

[0-572]   exon skip 24%   P2
-11 nt 27%
regular 21%
intron retention 28%

G>A

[0-419]   regular 83%   Control 1

intron retention 17%

Exon: 6   7
17734836   17734995   17739154   17739111

Figure 4

Click here to access/download;Figure;Figure4_DS.tif ±

Figure 5

Click here to access/download;Figure;Figure5_DS.tif

A

GOLGI TRANSPORT

PROTEIN FOLDING

CALCIUM TRANSPORT

ERAD-UPR

MITOCHONDRIAL SIGNALING

MITOSIS

TRANSLATION

NUCLEO-CYTOPLASMIC TRANSPORT

B

Reducing

β-lactamase | TMX2 | β-lactamase | TMX2 | β-lactamase | TMX2

150 kDa

100 kDa   Lac-Myc

37 kDa   TMX2-Myc

Pulldown SERCA2 | Pulldown Calnexin | IP Input

Figure 6

Figure 7

Click here to access/download;Figure;Figure7_DS.tif ⬇